CanaQuest Medical (CANQF) 10-Q 30 Jan 19 2018 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Dec. 31, 2017	Jan. 16, 2019
Document And Entity Information
Entity Registrant Name	Algae Dynamics Corp.
Entity Central Index Key	1,607,679
Document Type	10-Q
Document Period End Date	Dec. 31, 2017
Amendment Flag	false
Current Fiscal Year End Date	--03-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding		20,136,377
Trading Symbol	ADYNF
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2,018

Condensed Interim Balance Sheet

Condensed Interim Balance Sheets (Unaudited) - CAD ($)	Dec. 31, 2017	Mar. 31, 2017
Current Assets
Cash	$ 5,139	$ 87
Prepaid expenses	27,881	32,878
Amounts receivable, net	5,806	11,963
Advances to shareholders and related parties (Note 11)	54,596
Total Current Assets	93,422	44,928
Equipment and leasehold improvements, net (Note 3)	36,048	47,828
Total Assets	129,470	92,756
Current Liabilities
Accounts payable and accrued liabilities	382,963	286,792
Advances from shareholders and related parties (Note 4)		22,347
Promissory note (Note 6a)		16,456
Term loan (Note 5)	51,223	48,894
Convertible notes (Note 6b, 6c and 6d)	74,232	26,076
Convertible notes, short term (Note e)	54,506
Derivative liability (Note 7)	65,863	260,677
Warrant liability (Note 8b)	59,949	236,200
Total Current Liabilities	688,736	897,442
Going Concern (Note 1)
Commitments and Contingencies (Note 10)
STOCKHOLDERS' (DEFICIENCY)
Common stock (Note 8a), no par value, unlimited amount authorized, 14,013,708 issued and outstanding as of December 31, 2017, (March 31, 2017 - 13,337,521)	4,259,176	4,313,931
Additional paid in capital (Notes 8b and 8c)	1,180,662	1,016,324
Equity to be issued (Note 8a)	430,488
Accumulated deficit	(6,429,592)	(6,134,941)
Total Stockholders' (Deficiency)	(559,266)	(804,686)
Total Liabilities and Stockholders' (Deficiency)	$ 129,470	$ 92,756

Condensed Interim Balance She_2

Condensed Interim Balance Sheets (Unaudited) (Parenthetical) - $ / shares	9 Months Ended	12 Months Ended
	Dec. 31, 2017	Mar. 31, 2017
Statement of Financial Position [Abstract]
Common stock, no par value
Common stock, shares authorized	Unlimited	Unlimited
Common stock, shares issued	14,013,708	13,337,521
Common stock, shares outstanding	14,013,708	13,337,521

Condensed Interim Statements of

Condensed Interim Statements of Operations (Unaudited) - CAD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016
OPERATING EXPENSES
Accretion expenses (Notes 5 and 6)	$ 75,556	$ 13,941	$ 220,100	$ 22,897
Application and membership fees	3,282	3,247	10,095	9,740
Amortization expense (Note 3)	1,662	4,356	11,780	13,068
Bad debt recovery (Note 11)			(8,300)
Business development	1,752	1,309	2,629	5,767
Fair value change in derivative liability (Note 7)	(201,105)		(319,949)
Foreign exchange recovery	6,471	2,034	(2,814)	2,352
Gain on settlement of debt (Note 7c)				(72,924)
Interest	37,279	1,863	79,244	3,564
Loss on extinguishment of debt (Note 6, 10a and 13)		471,412		544,066
Management fees (recovery)			(8,125)
Occupancy costs	8,835	7,981	25,332	23,028
Office and general	(2,184)	1,040	5,044	3,413
Professional fees (Notes 8a, 8b, 8c and 12e)	29,529	258,484	69,623	743,738
Research and development	61,773	1,030	111,773	6,195
Stock based compensation (Note 8c)	62,914	158,573	96,448	436,127
Telephone and internet services	3,227	3,290	8,702	8,720
Travel	1,441	5,018	9,179	14,682
Total Operating Expenses	90,433	933,578	310,761	1,764,433
Net loss before income taxes	90,433	933,578	310,761	1,764,433
Deferred income tax recovery		(17,913)		(17,913)
Net Loss for the Period	$ 90,433	$ 915,665	$ 310,761	$ 1,746,520
Net loss per common share - basic and diluted	$ 0.01	$ 0.09	$ 0.02	$ 0.17
Weighted average common shares outstanding - basic and diluted	14,013,708	10,589,979	13,500,567	10,138,140

Condensed Interim Statements _2

Condensed Interim Statements of Stockholders' Equity (Deficiency) (Unaudited) - 9 months ended Dec. 31, 2017 - CAD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Equity to be Issued [Member]	Accumulated Deficit [Member]	Total
Balance at Mar. 31, 2017	$ 4,313,931	$ 1,016,324		$ (6,134,941)	$ (804,686)
Balance, shares at Mar. 31, 2017	13,337,521
Warrants expired (Note 8b)		(16,110)		16,110
Stock based compensation shares cancelled (Notes 8a)	$ (84,000)				(84,000)
Stock based compensation shares cancelled (Notes 8a), shares	(600,000)
Stock options		81,448			81,448
Stock based compensation transferred to Deferred share units, with the cancellation completed after the year end (Note 8a)		99,000			99,000
Stock based compensation transferred to Deferred share units, with the cancellation completed after the year end (Note 8a), shares	1,050,000
Deferred Share Units issued
Commitment shares issued on convertible note (Notes 6c and 6d)	$ 25,245				25,245
Commitment shares issued on convertible note (Notes 6c and 6d), shares	200,000
Shares to be issued for conversion convertible notes (Note 6e)			403,303		403,303
Shares issued to consultants as compensation for services (Note 8a)	$ 4,000				$ 4,000
Shares issued to consultants as compensation for services (Note 8a), shares	26,187				26,187
Shares to be issued to consultants as compensation for services (Note 8a),			27,185		$ 27,185
Shares to be issued to consultants as compensation for services (Note 8a), shares
Net loss for the period				(310,761)	(310,761)
Balance at Dec. 31, 2017	$ 4,259,176	$ 1,180,662	$ 430,488	$ (6,429,592)	$ (559,266)
Balance, shares at Dec. 31, 2017	14,013,708

Condensed Interim Statements _3

Condensed Interim Statements of Cash Flows (Unaudited) - CAD ($)	9 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Cash flows from operating activities
Net loss for the period	$ (310,761)	$ (1,746,520)
Adjustments to reconcile net loss to net cash used in operating activities:
Accretion expense	220,100	22,897
Amortization	11,780	13,068
Change in warrant liability (Note 8b)	(203,000)	16,042
Deferred income tax recovery		(17,913)
Fair value change in derivative liability (Note 7)	(319,949)
Foreign exchange (recovery)	(13,434)	52
Gain on settlement of debt		(72,924)
Loss on extinguishment of debt		544,066
Shares issued and to be issued for services (Note 8a)	31,186	585,351
Stock based compensation (Note 8c)	96,448	436,127
Change in operating assets and liabilities
Prepaid expenses	4,997	(8,050)
Amounts receivable	6,157	398
Accounts payable and accrued liabilities	114,606	26,839
Net cash flows used in operating activities	(361,871)	(200,297)
Cash flows from financing activities
Advances from shareholders	(76,943)	93,061
Convertible notes	578,123	67,595
Convertible note repaid	(70,482)
Promissory note repaid	(63,775)
Term loan proceeds		40,000
Warrant exercise proceeds		2,318
Net cash flows from financing activities	366,923	202,974
Net change in cash	5,052	2,677
Cash position - beginning of period	87	173
Cash position - end of period	5,139	2,850
Supplemental Information:
Income taxes paid
Interest paid
Common shares and shares to be issued for services (Note 8a)	100,000	686,931
Common shares issued for debt settlement and conversion of convertible debt	$ 2,541,781	$ 1,065,152

Nature of the Business and Goin

Nature of the Business and Going Concern	9 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Nature of the Business and Going Concern	1.) Nature of the Business and Going Concern Algae Dynamics Corp. (the “Company”) was incorporated under the Canada Business Corporations Act on October 7, 2008 as Converted Carbon of Canada Corp. On November 19, 2010, the Company amended its Articles of Incorporation to change its name to Converted Carbon Technologies Corp. and a further amendment was approved by the shareholders on August 28, 2014 to change the name to Algae Dynamics Corp. The Company is conducting research through sponsored research agreements with two universities to support development of health products utilizing cannabis and algae oil. The Company’s planned principal operations are the development and sale of health products, design and development of a facility to extract botanical oils, and design, engineering and manufacturing of a proprietary algae cultivation system for the high-volume production of pure contaminant-free algae biomass. The Company’s activities are subject to significant risks and uncertainties, including failing to obtain patents and failing to secure additional funding to operationalize the Company’s current technology before another company develops similar technology. These unaudited condensed interim financial statements have been prepared on the basis of a going concern, which contemplates the realization of assets and the settlement of liabilities in the normal course of business. The Company is in the development stage and has not yet realized profitable operations and has relied on non-operational sources to fund operations. The Company has suffered recurring losses and additional future losses are anticipated as the Company has not yet been able to generate revenue. In addition, as of December 31, 2017, the Company has a working capital deficiency of $595,314 (March 31, 2017 - $852,514) and an accumulated deficit of $6,429,592 (March 31, 2017 - $6,134,941). The Company’s ability to continue as a going concern is dependent on successfully executing its business plan, which includes the raising of additional funds. The Company will continue to seek additional forms of debt or equity financing, but it cannot provide assurances that it will be successful in doing so. These circumstances raise substantial doubt as to the ability of the Company to meet its obligations as they come due and accordingly, the appropriateness of the use of accounting principles applicable to a going concern. The accompanying financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. Such adjustments could be material.

Presentation of Financial State

Presentation of Financial Statements	9 Months Ended
	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Presentation of Financial Statements	2.) Presentation of Financial Statements Basis of Presentation These unaudited condensed interim financial statements should be read in conjunction with the financial statements for the Company’s most recently completed fiscal year ended March 31, 2017. These unaudited condensed interim financial statements do not include all disclosures required in annual financial statements, but rather are prepared in accordance with recommendations for interim financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). These unaudited condensed interim financial statements have been prepared using the same accounting policies, and methods as those used by the Company in the annual financial statements for the year ended March 31, 2017, except when disclosed below. The unaudited condensed interim financial statements contain all adjustments (consisting of only normal recurring adjustments) which are necessary to present fairly the financial position of the Company as at December 31, 2017, and the results of its operations for the nine month periods ended December 31, 2017 and 2016 and its cash flows for the nine month periods ended December 31, 2017 and 2016. Note disclosures have been presented for material updates to the information previously reported in the annual financial statements. Estimates The preparation of the financial statements in accordance with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual amounts could materially differ from these estimates. The significant areas requiring the use of management estimates are related to provision for doubtful accounts, accrued liabilities, contingencies, the valuation of deferred taxes, stock based compensation, warrants, convertible debt and intangible assets. Although these estimates are based on management’s knowledge of current events and actions management may undertake in the future, actual results may ultimately differ materially from those estimates. New Accounting Pronouncements ASU No. 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes, was issued to simplify the classification of deferred taxes on the balance sheet. The new guidance would require that deferred taxes be classified as non-current assets and liabilities based on the tax paying jurisdiction. Application of the standard, which can be applied prospectively or retrospectively, is required for fiscal years beginning on or after December 15, 2016 and for interim periods within that year. The adoption of the amended guidance on April 1, 2017 did not have a material impact on the Company’s financial statements. ASU No. 2016-01, Financial Instruments-Overall (Subtopic 825-10) - Recognition and Measurement of Financial Assets and Financial Liabilities, which addresses certain aspects of recognition, measurement, presentation, and disclosure of financial instruments. Most notably, this new guidance requires equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income. This new guidance is effective for annual reporting periods beginning after December 15, 2017. The guidance is not expected to have a material impact on the Company’s financial statements. ASU No. 2016-02, Leases (Topic 842) - On February 25, 2016, the FASB issued a new standard which requires lessees to recognize almost all leases on their balance sheet as a right-of-use asset and a lease liability. The new guidance will require the asset and liability to be initially measured at the present value of the lease payments in the statement of financial position. The new guidance will also require the company to recognize interest expense on the lease liability separately from the amortization of the right-use-asset for finance leases and recognize a single lease cost allocated on a straight-line basis over the lease term for operating leases, in the statement of comprehensive income. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years with early application permitted. The Company is currently evaluating this guidance to determine the impact it may have on the Company’s financial statements. ASU No. 2016-09, Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The ASU includes multiple provisions intended to simplify various aspects of the accounting for share-based payments. The areas of simplification in the update involve several aspects of accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows, however, some of the areas for simplification apply only to non-public entities. This guidance is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. The guidance, as adopted on April 1, 2017, did not have a material impact on the Company’s financial statements. ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. The ASU provides clarity to preparers on the treatment of eight specific items within an entity’s statement of cash flows. The guidance becomes effective for all public entities in fiscal years beginning after December 15, 2017, including interim periods therein. The guidance is not expected to have a material impact on the Company’s financial statements. ASU No. 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting. The ASU amends the scope of modification accounting for share-based arrangements and provides guidance on the types of changes to the terms or conditions of share-based payment awards to which an entity would be required to apply modification accounting under ASC 718. The guidance becomes effective for annual reporting periods, including interim periods within those annual reporting periods, beginning after December 15, 2017. The guidance is not expected to have a material impact on the Company’s financial statements.

Equipment and Leasehold Improve

Equipment and Leasehold Improvements	9 Months Ended
	Dec. 31, 2017
Property, Plant and Equipment [Abstract]
Equipment and Leasehold Improvements	3.) Equipment and Leasehold Improvements December 31, 2017 March 31, 2017 Accumulated Accumulated Cost Depreciation Cost Depreciation Computer equipment $ 3,558 $ 2,761 $ 3,558 $ 2,530 Production equipment 67,367 40,419 67,367 35,663 Leasehold improvements 42,290 33,987 42,290 27,194 Total $ 113,215 $ 77,167 $ 113,215 $ 65,387 Net carrying amount $ 36,048 $ 47,828 During the nine month period ended December 31, 2017, the Company recorded total amortization of $11,780 (December 31, 2016 - $13,068) which was recorded to amortization expense on the condensed interim statements of operations.

Advances from Shareholders

Advances from Shareholders	9 Months Ended
	Dec. 31, 2017
Related Party Transactions [Abstract]
Advances from Shareholders	4.) Advances from Shareholders As at December 31, 2017, the Company had received cumulative net working capital advances in the amount of $Nil (March 31, 2017 - $22,347) from two shareholders who are also officers and directors of the Company. The advances from shareholders are unsecured, non-interest bearing and payable upon demand.

Term Loans

Term Loans	9 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
Term Loans	5.) Term Loans (a) Term loan issued May 4, 2016 On May 4, 2016, the Company agreed to a term loan of $40,000 for bridge financing with a relative of one of the officers of the Company. The loan matured on November 30, 2017 and the terms specified a 30% premium to be paid at that time. The 30% premium is recognized as an expense over the term of the loan and is amortized on the condensed interim statements of operations. During the three and nine month periods ended December 31, 2017 the Company recorded accretion expense of $777 and $2,930, respectively (2016 - $2,000 and $10,956, respectively). The loan was initially scheduled to mature on August 28, 2016 but an extension was agreed to with the same terms. The unsecured loan has been extended indefinitely until the Company has the appropriate liquidity to repay the initial loan plus the premium. (b) Term loan issued August 18, 2017 In order to satisfy the repayment terms of the securities purchase agreement and convertible note (see Note 6b) GHS Investments, LLC (“GHS”) and the Company agreed to a short term loan which was paid in full by the Company in November 2017.

Convertible Notes

Convertible Notes	9 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
Convertible Notes	6.) Convertible Notes The carrying values of the Company’s secured convertible notes consist of the following as of December 31, 2017 and March 31, 2017 respectively: Convertible Notes December 31, 2017 March 31, 2017 USD$50,000 face value convertible note due August 15, 2017 a $ - $ (26,076 ) USD$56,000 face value convertible note due August 18, 2017, b - (16,456 ) USD$50,000 face value convertible notes due June 21, 2018, c (37,009 ) - USD$50,000 face value convertible note due July 25, 2018, d (37,223 ) - USD$20,000 face value convertible note due January 2, 2018, e (24,731 ) - USD$25,000 face value convertible note due January 15,2018, e (29,775 ) - $ (128,738 ) $ (42,532 ) (a) Promissory Note On February 14, 2017, the Company issued a USD$50,000 ($65,350) face value convertible promissory note, due August 15, 2017 to Salamon Partners LLC (“Salamon”) for net proceeds of USD$47,500. which consisted of the principal amount, net of transaction cost of US$2,500. The Salamon Note accrues interest at 12% per annum, payable in cash at maturity. However, the principal amount, plus accrued interest, may be converted at the option of the holder at any time during the term to maturity into shares of our common stock at a variable conversion price of 65% of market per share subject to adjustment for capital reorganization events and subsequent sales by the Company of shares of its common stock at a price per share below the conversion price of the Salamon note. The Salamon Note also embodies certain traditional default provisions that are linked to credit or interest risks, such as bankruptcy proceedings, liquidation events and corporate existence. The Company has concluded that the embedded conversion option is not indexed to our stock due to the variability in the conversion price and the down-round protection features afforded to the holder as well as the foreign exchange rate fluctuations. Therefore, the embedded conversion option is subject to classification in the financial statements in liabilities at fair value both at inception and subsequently pursuant to ASC 480-10-25-14. On August 15, 2017, the Company paid a total of USD$53,000 ($67,591) which consisted of the principal amount due USD$50,000 ($63,775) plus accrued interest USD$3,000 ($3,816). During the three and nine month periods ended December 31, 2017, the Company recorded an accretion expense of $Nil and $48,499, respectively (2016 - $Nil and $Nil, respectively) as the discount to the carrying value of the notes. (b) Securities Purchase Agreement and Convertible Note On November 18, 2016, the Company issued a USD$56,000 ($76,382) face value secured convertible note, due August 18, 2017 to GHS for net proceeds of USD$50,000 ($67,595). The GHS Note is secured and accrues interest at 12% per annum, payable in cash at maturity. However, the principal amount, plus accrued interest, may be converted at the option of the holder at any time during the term to maturity into shares of our common stock at variable conversion price of 62% of market per share subject to adjustment for capital reorganization events and subsequent sales by the Company of shares of its common stock price per share below the conversion price of the GHS Note. The GHS Note also embodies certain traditional default provisions that are linked to credit or interest risks, such as bankruptcy proceedings, liquidation events and corporate existence. The Company has concluded that the embedded conversion option is not indexed to our stock due to the variability in the conversion price and the down-round protection features afforded to the holder as well as the foreign exchange rate fluctuations. Therefore, the embedded conversion option is subject to classification in the financial statements in liabilities at fair value both at inception and subsequently pursuant to ASC 480-10-25-14. During the fiscal year, the Company repaid the convertible note in full (see Note 5b). During the three and nine month periods ended December 31, 2017, the Company recorded an accretion expense of $Nil and $45,854, respectively (2016 - $11,941 and $11,941, respectively) as the discount to the carrying value of the notes. (c) Convertible Note – issued June 21, 2017 On June 21, 2017, the Company commenced a financing of up to USD$500,000 of one-year 12% convertible notes. The notes are convertible at the option of the holder into common shares of the Company at a price of USD$0.25 per share, and are subject to mandatory conversion if the volume-weighted trading price of the common shares is greater than USD$1.00 per share for twenty consecutive trading days so long as the underlying shares may be resold in compliance with the registration requirements of the Securities Act of 1933, as amended. In addition, the Company shall issue pro rata to the purchasers of the first USD$100,000 of notes an aggregate of 200,000 common shares as a commitment fee. On June 21, 2017, the Company issued two notes totaling USD$50,000 ($66,451). The Company also granted 200,000 common share purchase warrants to the holders of the USD$50,000 notes. Each warrant is exercisable into one common share at USD$0.50 for a period of five years. The Company has concluded that the embedded conversion option and warrants are not indexed to our stock due to the down-round protection features afforded to the holder and foreign exchange rate fluctuations. Therefore, the embedded conversion option and warrants are subject to classification in the financial statements in liabilities at fair value both at inception and subsequently pursuant to ASC 480-10-25-14. During the three and nine months periods ended December 31, 2017, the Company recorded an accretion expense of $13,939 and $29,086, respectively (2016 - $Nil and $Nil, respectively) as the discount to the carrying value of the notes. On June 21, 2018, the principals plus accrued interest were converted into common shares (560,000) at a price of USD$0.10 per share. The issuance of subsequent convertible notes (Note 6e) with an exercise price of USD$0.10 per share correspondingly reduced the exercise price for the June 21, 2017 convertible notes issued in accordance with the terms of the convertible notes. (d) Convertibles Notes – issued July 25, 2017 On July 25, 2017, the Company added a second one-year 12% convertible note as a continuation of the financings commenced with the convertibles notes on June 21, 2017 (Note 6a). The amount of this convertible note is USD$50,000 ($62,535). The note is convertible at the option of the holder into common shares of the Company at a price of USD$0.25 per share, and is subject to mandatory conversion if the volume-weighted trading price of the common shares is greater than USD$1.00 per share for twenty consecutive trading days so long as the underlying shares may be resold in compliance with the registration requirements of the Securities Act of 1933, as amended. In addition, the Company shall issue pro rata to the purchasers of the first USD$100,000 of notes an aggregate of 200,000 common shares as a commitment fee. The Company also granted 200,000 common share purchase warrants to the holder of the USD$50,000 note. Each warrant is exercisable into one common share at USD$0.50 for a period of five years. The Company have concluded that the embedded conversion option and warrants are not indexed to our stock due to the down-round protection features afforded to the holder and foreign exchange rate fluctuations. Therefore, the embedded conversion option and warrants are subject to classification in the financial statements in liabilities at fair value both at inception and subsequently pursuant to ASC 480-10-25-14. During the three and nine month periods ended December 31, 2017, the Company recorded an accretion expense of $11,542 and $19,798, respectively (2016 - $Nil and $Nil, respectively) as the discount to the carrying value of the notes. On July 25, 2018, the principal plus accrued interest was converted into common shares (560,000) at a price of USD$0.10 per share. The issuance of subsequent convertible notes (Note 6e) with an exercise price of USD$0.10 per share correspondingly reduced the exercise price for the July 25, 2017, convertible note issued in accordance with the terms of the convertible note. (e) Convertible Notes, short term – issued August to November 2017 The Company issued several convertible notes on August 14, 2017 with a face value of USD$53,000 ($67,602), maturity date of October 13, 2017, September 18, 2017 with a face value of USD$10,000 ($12,238), maturity date November 20, 2017, October 27, 2017 with face value of USD$250,000 ($321,850), maturity date December 27, 2017, November 1, 2017 with face value of USD$20,000, maturity date January 2, 2018, ($25,770) and November 13, 2017 with face value of USD$25,000 ($31,833), maturity date January 15, 2018 for a total of USD$358,000 ($459,293). The notes have all matured two months after issuance and converted into a total of 3,639,931 common shares at the conversion rate of USD$0.10 during the year. The Company issue 2,541,781 common shares during the fiscal year ending March 31, 2018 with the remaining 1,098,150 issued subsequent to March 31, 2018 (Note 13). The Company agreed to issue an additional 159,023 warrants with an exercise price of $0.75 and an expiry of January 2, 2020, in connection with conversions. During the period ended December 31, 2018, the Company recorded an accretion expense of $24,458 as the discount to the carrying value of the notes (2016 - $Nil). During the three and nine months periods ended December 31, 2017, the Company recorded an accretion expense of $50,075 and $74,533, respectively (2016 - $Nil and $Nil, respectively) as the discount to the carrying value of the notes. Accounting for the Secured Convertible and Promissory Notes The Company has evaluated the terms and conditions of the secured convertible notes issued on June 21, 2017 and July 25, 2017, under the guidance of ASC 815. Because the economic characteristics and risks of the equity-linked conversion options are not clearly and closely related to a debt-type host, the conversion features require classification and measurement as derivative financial instruments. The other embedded derivative features were also not considered clearly and closely related to the host debt instruments. Further, these features individually were not afforded the exemption normally available to derivatives indexed to a company’s own stock. Accordingly, the evaluation resulted in the conclusion that this compound derivative financial instrument requires bifurcation and liability classification, at fair value. The compound derivative financial instrument consists of (i) the embedded conversion features and the (ii) down-round protection features. Current standards contemplate that the classification of financial instruments requires evaluation at each report date. Discounts on the convertible notes arise from (i) the allocation of basis to other instruments issued in the transaction, (ii) fees paid directly to the creditor and (iii) initial recognition at fair value, which is lower than face value. The discount to the carrying value of the convertible notes is being amortized as a non cash interest expense over the term of the promissory note using the effective interest rate method. Amortization of discounts on the convertible notes in accretion expense amounted to $220,100 during the nine month period ended December 31, 2017 (December 31, 2016 - $22,897).

Derivative Liability

Derivative Liability	9 Months Ended
	Dec. 31, 2017
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Liability	7.) Derivative Liability The Company follows the provisions of ASC 820 with respect to our financial instruments. As required by ASC 820, assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to their fair value measurement. The derivative financial instruments which are required to be measured at fair value on a recurring basis under of ASC 815 as of December 31, 2017 and 2016 respectively, are all measured at fair value using Level 1 inputs. Level 1 inputs are observable inputs that are supported by market activity. The compound embedded derivative and warrants were valued using a binomial-lattice-based valuation model. The lattice-based valuation technique was utilized because it embodies all the requisite assumptions (including the underlying price, exercise price, term, volatility, and risk-free interest-rate) that are necessary to fair value these instruments. For forward contracts that contingently require net-cash settlement as the principal means of settlement, the Company projects and discounts future cash flows applying probability-weighted to multiple possible outcomes. Estimating fair values of derivative financial instruments requires the development of significant and subjective estimates that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors. In addition, option-based techniques are highly volatile and sensitive to changes in the trading market price of our common stock. Because derivative financial instruments are initially and subsequently carried at fair values, the income will reflect the volatility in these estimate and assumption changes. The following table sets forth (i) the range of inputs for each significant assumption and (ii) the equivalent, or averages, of each significant assumption as of December 31, 2017: Compound Embedded Derivative: December 31, 2017 March 31, 2017 Stock Price $ 0.071 USD $ 0.23 USD Risk free rate 1.76 % 1.02 % Expected volatility 179 % 308 % Conversion/Exercise price $ 0.07 USD $ 0.145 USD Expected dividend rate 0 % 0 % Expected life (in years) 0.47 0.38 Derivative Liability Warrants December 31, 2017 March 31, 2017 Stock Price $ 0.071 USD N/A Risk free rate 2.20 % N/A Expected volatility 212 % N/A Conversion/Exercise price $ 0.50 USD N/A Expected dividend rate 0 % N/A Expected life (in years) 4.47 N/A

Capital Stock

Capital Stock	9 Months Ended
	Dec. 31, 2017
Equity [Abstract]
Capital Stock	8.) Capital Stock (a) Common Shares Authorized The Company is authorized to issue an unlimited number of common shares with no par value. Issued and Outstanding Under the terms of convertible notes issued on June 21, 2017, for USD$50,000 ($66,550), the Company agreed to issue 100,000 common shares valued using convertible debt issue market share price at $13,989 as a commitment fee. The note matured on June 21, 2018 and a total of 560,000 common shares were issued on maturity plus 200,000 purchase warrants were also issued on June 21, 2017. One purchase warrant can be exchanged for one common share for USD$0.50 at any time until June 21, 2022. Under the terms of a convertible note issued on July 25, 2017, for USD$50,000 ($62,535), the Company agreed to issue 100,000 common shares valued using convertible debt issue date market share price at $11,256 as a commitment fee. The note matured on July 25, 2018 and a total of 560,000 common shares were issued on maturity plus 200,000 purchase warrants were also issued on July 25, 2017. One purchase warrant can be exchanged for one common share for USD$0.50 at any time until July 25, 2022. On November 8, 2017, the Board approved the award of an aggregate of 1,050,000 common shares to three management personnel for services rendered, these shares were subsequently cancelled and awarded as deferred share units. In addition, the Board cancelled an aggregate of 600,000 common shares awarded in a prior period to three management personnel. On December 1, 2017, the Company entered into an agreement with 908746 Ontario Inc., for the provision of advisory services for ongoing capital market activities including investor relations. Under the terms of this agreement, a total of 26,187 were issued for professional services during the period ended December 31, 2017. Equity to be issued On April 9, 2017, the Company signed a 12-month consulting agreement. The terms of the agreement include the provision of 100,000 common stock on signing, valued at USD$20,390 ($27,186). See Note 10. Under the terms of the convertible notes issued October to November 2017 (Note 6 (e)), four of the convertibles notes had matured and the Company had a commitment to issue 3,182,219 Common shares. The shares were issued subsequent to December 31, 2017. Equity Purchase Agreement (“EPA”) On September 10, 2015, the Company entered into the EPA. The holder of the EPA was committed to purchase up to USD$750,000 worth of the Company’s common shares (the “Put Shares”) over the 12-month term of the EPA. The Company paid to the holder of the EPA a commitment fee for entering into the EPA equal to 50,000 restricted common shares of the Company, valued at $67,195, based on the stock price in the most recent private placement as the Company’s shares had not yet begun to trade on a public market. On June 23, 2016, the Company agreed in conjunction with RY Capital Group, LLC and GHS Investments, LLC to assign the EPA to GHS Investments, LLC. The Company has notified the holder of the EPA that the facility will not be utilized and there is no cancellation fee or any commitment. (b) Warrants As at December 31, 2017, the following warrants were outstanding: Fair Value at December 31, 2017 Expiration Date Number of Warrants Number of Warrants Exercisable Weighted Average Exercise Price of Vested Warrants – Liability December 31, 2018, ii.) 275,000 50,000 USD$ 0.04 $ (0.05 ) $ 2,600 January 17, 2022, iii.) 900,000 900,000 USD$ 0.65 $ (0.83 ) $ 30,600 June 21, 2022, iv.) 200,000 200,000 USD$ 0.50 $ (0.63 ) $ 13,352 July 25, 2022, v.) 200,000 200,000 USD$ 0.50 $ (0.63 ) $ 13,397 1,575,000 1,350,000 $ 0.64 $ 59,949 i.) ii.) iii.) iv.) v.) 8ASC 815 “Derivatives and Hedging” indicates that warrants with exercise prices denominated in a currency other than an entity’s functional currency should not be classified as equity. As a result, warrants with a USD exercise price have been treated as derivatives and recorded as liabilities carried at their estimated fair value, with period-to-period changes in the fair value recorded as a gain or loss in the statements of operations. The continuity of warrants for the period ended December 31, 2017 as follows: Number Weighted Average of Warrants Exercise Price Balance, March 31, 2017 1,197,500 $ 0.68 Issued 400,000 $ 0.64 Expired, unexercised (22,500 ) $ 1.12 Balance, December 31, 2017 1,575,000 $ 0.64 As at December 31, 2017, the fair value of the 1,575,000 (March 31, 2017 – 1,175,000) warrants exercisable was $71,649 (March 31, 2017 - $298,700) which was estimated using the option pricing models based on the assumptions mentioned in Note 8 b) ii.) to b) vi.). Of this amount, $59,949 (March 31, 2017 - $236,200) was reflected as a liability as at December 31, 2017, representing the percentage of the fair value of the warrants that is equal to the percentage of the requisite service that has been rendered at December 31, 2017. The warrant liability is classified as Level 3 within the fair value hierarchy (See Note 12). The Company’s computation of expected volatility during the nine months ended December 31, 2017 and 2016 is based on the market close price of comparable public entities over the period equal to the expected life of the warrants. The Company’s computation of expected life is calculated using the contractual life. (c) Stock-based compensation The Company’s stock-based compensation program (the “Plan”) includes stock options in which some options vest based on continuous service. For those equity awards that vest based on continuous service, compensation expense is recorded over the service period from the date of grant. The maximum number of options that may be issued under the plan is floating at an amount equivalent to 15% of the issued and outstanding common shares, or 2,102,056 as at December 31, 2017 (March 31, 2017 – 2,000,628). The total number of options outstanding as at December 31, 2017 was 1,545,000 (2016 – 930,000). On November 10, 2017, 850,000 options were granted to officers and consultants of the Company. The exercise price of these options is $0.15. Of this grant 680,000 options vest as to one-third on the grant date and one-third on each of the first anniversary and the second anniversary of the grant date; 170,000 options vest as to one quarter on the date of grant and one quarter at 90 days, 180 days and 270 days from the grant date. The activities in options outstanding are as noted below: Number of Weighted Average Options Exercise Price Balance, March 31, 2017 695,000 $ 0.99 Granted 850,000 $ 0.15 Balance, December 31, 2017 1,545,000 $ 0.53 The following table presents information relating to stock options outstanding and exercisable at December 31, 2017. Options Outstanding Options Exercisable Weighted Weighted Average Weighted Average Remaining Average Remaining Number of Contractual Number of Exercise Contractual Exercise Price Options Life (Years) Options Price Life (Years) $ 1.73 185,000 1.96 185,000 $ 1.73 1.96 $ 2.43 85,000 3.02 85,000 $ 2.43 3.02 $ 0.38 425,000 3.82 311,667 $ 0.38 3.82 $ 0.15 850,000 4.83 269,167 $ 0.15 4.83 $ 0.53 1,545,000 4.11 850,833 $ 0.53 3.66

Income Taxes

Income Taxes	9 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Income Taxes	9.) Income Taxes The Company has no taxable income under Canadian Federal and provincial tax laws for the three and nine month periods ended December 31, 2017 and 2016. The Company has non-capital loss carryforwards at December 31, 2017, total of approximately $3,948,000, which may be offset against future taxable income. If not used, the loss carryforwards will expire between 2019 and 2037.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	10.) Commitments and Contingencies The Company entered into a five year operating lease for office and production facilities. The lease commenced on December 1, 2013 and expires on November 30, 2018. The base monthly rental is $1,390 plus the Company’s estimated portion of property taxes and operating expenses which are currently $847 per month. The Company has agreed to extend the lease to November 30, 2021. Under the terms of the extended lease the base monthly rental is $1,853 in 2019, $1,946 in 2020, and $2,039 in 2021. The future commitments pursuant to this lease extension, including property taxes and operating expenses for the fiscal periods ending March 31 are: 2018 (remaining) $ 6,867 2019 $ 28,685 2020 $ 32,763 2021 $ 33,875 2022 $ 23,500 For the three and nine month periods ended December 31, 2017, occupancy costs related to this lease were $6,544 and $19,679 (December 31, 2016 – $6,500 and $19,499). On March 11, 2014, and as amended on July 18, September 3, 2014, September 5, 2014, December 31, 2015 and again on December 20, 2016, the Company entered into a consulting agreement with Connectus, Inc. (“Connectus”) to assist and advise the Company in matters concerning corporate finance and the Company’s current and proposed financing activities for the period commencing April 1, 2014 and ending December 31, 2014. Pursuant to this agreement, the Company agreed to issue to Connectus, 625,000 warrants of the Company. Each warrant is exercisable at USD$0.04 ($0.054) per share for a period of three years. Of the warrants granted, 300,000 vested on September 3, 2014 with the unvested portion vesting pro-rata for each USD$250,000 ($335,675) raised in an offering, fully vesting upon USD$1,500,000 ($2,014,050) being raised. During the year ended March 31, 2015, the President of Connectus became a director of the Company. On December 31, 2015, the Company extended the contract to December 31, 2016. In consideration of the contract extension, the Company issued 93,000 common shares to Connectus as compensation, which has been recorded as professional fees on the statements of operations during the year ended March 31, 2016. On December 27, 2016, the Company extended the contract and expiry date of the warrants to December 31, 2017. On January 23, 2017, the Company approved the vesting of 100,000 warrants. Connectus assigned the warrants to Apollo Marketing, LLC. On January 15, 2018, the Company extended the contract and expiry date of the warrants to December 31, 2018. The Company agreed to extend the vested warrants to March 31, 2019. On April 23, 2014, the Company entered into employment agreements with three officers of the Company effective July 1, 2014. The initial contracts contain minimum aggregate commitments of approximately $427,000 per year for three years and additional contingent payments of up to approximately $600,000 in aggregate upon the occurrence of a change of control. As a triggering event has not taken place, the contingent payments have not been reflected in these financial statements. If employment is terminated by the Company other than upon a change of control or for just cause, the officers will be entitled to an amount equal to twelve months compensation including benefits, which shall be increased by one month for each full year of service completed. The employment agreements were amended whereby any salary from the commencement of the employment agreements has been waived until such a time when the Company is able to raise additional financing. Salaries will be earned based upon the Company’s success in raising future capital in accordance with the following schedule: Cumulative Funds Raised 1 Effective Monthly Salary % $ 100,000 10.0 % $ 175,000 15.0 % $ 250,000 25.0 % $ 375,000 37.5 % $ 500,000 50.0 % $ 750,000 62.5 % $ 1,000,000 75.0 % $ 1,250,000 87.5 % $ 1,500,000 100.0 % 1 On May 19, 2016, the Company signed a consulting agreement with an agent in connection with proposed placements of up to USD$10,000,000 ($13,427,000) in a combination of equity and or debt of the Company for a term of one year. Consideration payable under the consulting agreement include a non-refundable equity retainer of 100,000 common shares of the Company, a placement fee equal to 8% of the gross purchase price paid for equity of the Company, an administrative fee of 4% of the gross purchase price paid for equity, a placement fee of 4% of the gross purchase price paid for non-convertible debt and warrants to purchase common shares of the Company equal to 8% of the number of shares of common stock issuable by the Company upon exercise or conversion of any and all securities issued at each closing. On January 10, 2017, the Company entered into an addendum to the agreement signed on May 19, 2016 which provided for a grant of 900,000 warrants at an exercise price of USD$0.65 ($0.86) for a period of five years with a cashless exercise option. On August 15, 2017, the Company extended the contract for an additional year. On February 23, 2017, the Company entered into a three year sponsored research contract with the University of Waterloo commencing on April 1, 2017. Under the terms of the agreement the Company will contribute $130,000 upon start date of the project, $130,000 on completion of Year 1 and $130,000 on completion of Year 2, plus the Company will make an in-kind contribution valued at $70,000 in each of the 3 years. Any patents initiated by the Company from the sponsored research will be assigned to the Company and in return the Company will pay the researcher $10,000 per patent filed, $40,000 per patent issued by the U.S. patent office, $50,000 per product after the first commercial sale and $50,000 per product once the gross sales exceed $1,000,000. As of December 31, 2017, the Company has made a payment of $30,000 pursuant to this agreement. As of November 30, 2018 the Company has made payments totaling $130,000 under the terms of the payment schedule agreed to with the University. On March 13, 2017, the Company entered into a four year sponsored research contract with the University of Western Ontario commencing on April 1, 2017. Under the terms of the agreement the Company will contribute $210,000 upon execution of the agreement, $210,000 on completion of Year 1, $210,000 on completion of Year 2 and $210,000 on completion of Year 3, plus the Company will make an in-kind contribution valued at $62,500 in each of the 4 years. Any patents initiated by the Company from the sponsored research will be assigned to the Company and in return the Company will pay the researcher $10,000 per patent filed, $40,000 per patent issued by the U.S. patent office, $50,000 per product after the first commercial sale and $50,000 per product once the gross sales exceed $1,000,000. As of December 31, 2017, the Company has made payments totaling $80,000 pursuant to this agreement. As of November 30, 2018, the Company had made additional payments totaling $230,000 pursuant to the terms of the agreement as agreed to with the University. On March 27, 2017, the Company entered into a one year agreement with Questrade, Inc. an Investment Dealer to provide guidance on the trading of the Company’s securities and guidance with respect to the promotion of the Company. The Company shall pay Questrade a monthly fee in an amount equal to USD$5,500 for consulting services rendered each month of the term. Questrade filed a statement of claim in the amount of $29,941 in small claims court and the matter has had an initial trial date with a subsequent date scheduled for March 14, 2019. On April 9, 2017, the Company signed a 12 month consulting agreement effective April 15, 2017 with an arm’s length organization, The Eversull Group, Inc. to provide financial public relations, investor, shareholder, press relations and capital search consulting services. Terms of the agreement include the provision of 100,000 restricted shares annually, a minimum monthly retainer of USD$2,000 plus a 3% introduction fee for all sources of funding introduced by The Eversull Group, Inc. and accepted by the Company. The Company terminated the agreement. On April 19, 2017, the Company announced plans to form a joint venture corporation with Avanti Rx Analytics Inc. (ARA). The Company would own 96% of the joint venture and ARA would own 4%. As a result of signing the letter of Intent with Bonify on August 10, 2017 (details provided below) the Company will not be proceeding with the joint venture. The plans for this venture were cancelled after the year end. On May 8, 2017, the Company signed a consulting agreement with Carter, Terry & Company in connection with the proposed raising of capital in a combination of equity and/or debt of the Company for a term of two years. Terms of the agreement include the issuance of 150,000 restricted common shares on signing (see Note 8(a)) plus future consideration payable under the consulting agreement, including a placement fee equal to 10% of the gross proceeds raised less than USD$1,000,000 and 8% for gross funds raised in excess of USD$1,000,000, plus the equivalent amount of restricted shares equal to 4% of the capital raised divided by the closing price of the stock on the date of close for a period of two years. Notification has been provided to the Carter, Terry & Company that the consulting agreement is cancelled and the Company will not be making any payments. This agreement was subsequently cancelled with no further obligations by the Company and the shares were not issued. On August 8 2017, the Company signed a non-binding Letter of Intent (LOI) with 6779264 Manitoba Ltd. dba Bonify (“Bonify”). Bonify is a licensed producer, pursuant to the Access to Cannabis for Medical Purposes Regulations in Canada. In the LOI, the Company and Bonify have outlined the following: i) The purchase and installation of cannabis oil extraction equipment with an estimated cost of $1,450,000 to be jointly agreed upon by the Company and Bonify with the equipment being located in Bonify’s facility. At the end of the agreement, full right and title to the equipment would be assigned to Bonify; ii) The processing of cannabis material supplied by Bonify and other licensed producers in the oil extraction facility; iii) The supply of cannabis oil and algae omega-3 oils to The University of Waterloo and University of Western Ontario to support the sponsored research agreements that the Company has in place with the two universities (See Note 10); iv) The sharing of direct expenses, and, after adjustment for the market value of cannabis material supplied by Bonify and third parties, sharing of revenues from the sale of cannabis oil and algae-cannabis oil products; and v) The negotiation of a definitive agreement no later than September 30, 2017. The definitive agreement was not completed. This letter of intent was subsequently abandoned and the Company has no additional obligations. The Company, as the industry partner, is the participant in a Project Grant of up to $400,000 from the Mitacs Accelerate program, that will be delivered directly to Western University through eligible internships. The financial contribution by the Company which is $180,000 for this grant is part of the funding included in the research agreement the Company signed with the university and announced on March 13, 2017. To-date the Company has paid the initial of two installments to Mitacs, with the remaining installments being invoiced by Mitacs to the Company throughout the duration of the project. The balance of the $400,000 award ($220,000) will be provided by Mitacs. The project started on December 1, 2017 and is scheduled to operate for two (2) years. The extent of the announced award from Mitacs of $400,000 to be paid directly to the university by Mitacs is dependent on the funding provided by the Company and the number of interns employed in the project. The Company has paid $30,000 with a further commitment of $24,000 in 2017 – 2018. The commitment by the Company for 2018 – 2019 is $66,000 and in 2019 – 2020 is $60,000. On August 15, 2017, the Company engaged a Canadian firm, Kernaghan and Partners Ltd. (the “Agent”) a fully regulated full service brokerage firm to conduct a capital raise in the Canadian market. In consideration of the services to be rendered, the Agent shall receive on the closing date of the offering: i) a work fee of $25,000; ii) cash commission (the “ iii) broker warrants entitling the Agent to purchase, equal to the issue price, the number of common shares that is equal to 6% of the number of common shares sold pursuant to the offering, except for sales to persons on the President’s List, in respect of which the broker warrants shall entitle the Agent to purchase the number of common shares that is equal to 2% of the number of common shares sold to such persons. The broker warrants shall have a term of 2 years and an exercise price equal to the offering price of the common shares.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Dec. 31, 2017
Related Party Transactions [Abstract]
Related Party Transactions	11.) Related Party Transactions Included in advances to shareholders and related parties is an amount of $54,596 from three officers of the Company as at December 31, 2017 (2016 - $21,064), who is also a director and officer of the Company for funds advanced under his employment agreement (See Note 10). The amount receivable is unsecured, non-interest bearing, repayable upon demand and $9,356 (2016 - $Nil) was offset by an allowance for doubtful accounts and a recovery of $8,300 is shown as a recovery on the condensed interim statements of operations for the period ended December 31, 2017.

Financial Instruments

Financial Instruments	9 Months Ended
	Dec. 31, 2017
Investments, All Other Investments [Abstract]
Financial Instruments	12.) Financial Instruments (a) Liquidity risk Liquidity risk is the risk that the Company will not have sufficient cash resources to meet its financial obligations as they come due. The Company’s liquidity and operating results may be adversely affected if its access to the capital market is hindered, whether as a result of a downturn in stock market conditions generally or matters specific to the Company. The Company generates cash flow primarily from its financing activities and advances from shareholders. As at December 31, 2017, the Company had cash of $5,139 (March 31, 2017 - $87) to settle current liabilities of $688,736 (March 31, 2017 - $897,442). All of the Company’s financial liabilities other than the warrant liability of $59,949 (March 31, 2017 - $236,200), the term loan of $51,223 (March 31, 2017 - $48,894), the convertible notes of $74,232 (March 31, 2017 - $26,076), short term convertible notes $54,506 (March 31, 2017 - $Nil) and derivative liability of $65,863 (March 31, 2017 - $260,677) have contractual maturities of less than 30 days and are subject to normal trade terms. The Company regularly evaluates its cash position to ensure preservation and security of capital as well as liquidity. In the normal course of business, management considers various alternatives to ensure that the Company can meet some of its operating cash flow requirements through financing activities, such as private placements of common stock, preferred stock offerings and offerings of debt and convertible debt instruments as well as through merger or acquisition opportunities. Management may also consider strategic alternatives, including strategic investments and divestitures. As future operations may be financed out of funds generated from financing activities, the ability to do so is dependent on, among other factors, the overall state of capital markets and investor appetite for investments in the cannabis industry and the Company’s securities in particular. Should the Company elect to satisfy its cash commitments through the issuance of securities, by way of either private placement or public offering or otherwise, there can be no assurance that the efforts to obtain such additional funding will be successful, or achieved on terms favorable to the Company or its existing shareholders. If adequate funds are not available on favorable terms, the Company may have to reduce substantially or eliminate expenditures or obtain funds through other sources such as divestiture or monetization of certain assets or sublicensing (where permitted) of certain rights to certain of the Company’s technologies or products. (b) Concentration of credit risk Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash deposits. Cash deposits with a major Canadian chartered bank are insured by the Canadian Deposit Insurance Corporation up to $100,000. As at December 31, 2017, the Company held $5,139 (March 31, 2017 - $87) with a major Canadian chartered bank. (c) Foreign exchange risk The Company principally operates within Canada. The Company’s functional currency is the Canadian dollar and major purchases are transacted in Canadian dollars. Certain of the Company’s debt obligations are denominated in U.S. dollars. Management does not hedge its foreign exchange risk. (d) Interest rate risk As at December 31, 2017, the Company does not have any non-fixed interest-bearing debt. Management believes that the interest rate risk concentration with respect to financial instruments included in assets and liabilities has been reduced to the extent presently practicable. (e) Derivative liability – embedded derivative and warrant liabilities In connection with the consulting and investment agreements, the Company granted warrants to purchase up to 1,575,000 common shares of the Company as disclosed in Note 8(b). The warrants have an exercise price of USD$0.04 ($0.05) for Connectus warrants, USD$0.65 ($0.83) for Midtown warrants and USD$0.50 ($0.63) for the investment placed in June and July 2017. The Connectus warrants are exercisable at any time prior to December 31, 2018 (See Note 10), the Midtown warrants are exercisable at any time prior to January 16, 2022, the warrants for the investments undertaken in June are exerciseable prior to June 21, 2022 and the warrants for the investment undertaken in July are exercisable prior to July 25, 2022. The warrants are accounted for as derivative liabilities because the exercise price is denominated in a currency other than the Company’s functional currency. Fair Value at Fair Value Measurement Using December 31, 2017 Level 1 Level 2 Level 3 Derivative liability – Warrants $ 59,949 $ - $ - $ 59,949 The table below sets forth a summary of changes in the fair value of the Company’s Level 3 financial liabilities (warrant derivative liability) for the periods ended December 31, 2017 and March 31, 2017: Nine months ended Year ended December 31, 2017 March 31, 2017 Balance at beginning of year $ 236,200 $ 27,479 Derivative instruments granted or vested 41,294 633,000 Derivative instruments exercised - (55,321 ) Change in fair market value, recognized in operations as professional fees (217,545 ) (368,958 ) Balance at end of period $ 59,949 $ 236,200 See Note 8(b). These instruments were valued using pricing models that incorporate the price of a share of common stock, expected volatility, risk free rate, expected dividend rate and expected estimated life. The Company estimated the value of the warrants issued for services using the Black-Scholes model and for convertible debt financings using the binomial-lattice-based valuation model. There were no transfers of assets or liabilities between Level 1, Level 2, or Level 3 during the periods ended December 31, 2017 and March 31, 2017. The following are the key weighted average assumptions used in connection with the estimation of fair value as at December 31, 2017: December 31, 2017 March 31, 2017 Number of shares underlying the warrants 1,575,000 1,175,000 Fair market value of the stock $ 0.071 $ 0.3061 Exercise price USD$ 0.5($0.64 ) USD$ 0.5($0.68 ) Expected volatility 212 % 229 % Risk-free interest rate 2.20 % 1.03 % Expected dividend yield 0 % 0 % Expected warrant life (years) 3.64 3.85

Subsequent Events

Subsequent Events	9 Months Ended
	Dec. 31, 2017
Subsequent Events [Abstract]
Subsequent Events	13.) Subsequent Events Subsequent to March 31, 2018 year end, the Company submitted a provisional patent which is a result of the research being undertaken at Western University under the terms of the Sponsored Research Agreement with the university. The provisional patent has been assigned to the Company. The provisional patent is applicable to the use of botanical oils in conjunction with cannabis oils for medical purposes. The Company has signed a supply agreement for the supply of cannabis flower for medical purposes. This supply agreement is in compliance with the cannabis regulations established by Health Canada. Under the terms of the agreement, the Company did not commit to a purchase volume. The Company has engaged a consultant to assist with an application to Health Canada to obtain a license to undertake the purchase/sale and import/export of medical cannabis without possession. Subsequent to the March 31, 2018 year end, the Company undertook the raising of additional capital. The capital raise initially consisted of a $100,000 convertible debenture which is exercisable into common shares of the Company at a fixed rate of $0.25 per share up until July 19, 2021. In addition, the Company completed a private placement in the amount of $947,117 issued at $0.40 per common share plus one-half warrant. A whole warrant can be exchanged for one common share at $0.75 per share up until October 26, 2020. On July 6, 2018, the Company signed an agreement with an arm’s length organization, Edgewater Consulting Corp to assist with the raising of capital funds. The agreements provides for a cash fee of $52,355 plus the allocation of 41,885 warrants at a price of $0.75 and the allocation of 150,000 stock options at a price of $0.50. The contract also provides for the provision of consulting services at $3,000 per month to assist with the application for a public listing on a Canadian Exchange. On October 1, 2018, the Company signed an agreement with an arm’s length individual to assist the Company with the public offering process. The terms of the agreement provide for the issuance of 50,000 Restricted Stock Units in accordance with the Stock incentive plan and a further 50,000 warrants at a price of $0.75 with an expiry date of October 26, 2020. In accordance with Note 6 (c), under the terms of the agreements with two of the holders of convertible notes with a maturity of 60 days the Company had a commitment to issue an additional 230,876 common shares. This commitment was settled subsequent to March 31, 2018 by issuing 115,438 warrants with an exercise price of $0.75 and an expiry of January 2, 2020. On January 15, 2018, 475,000 options were granted to officers and consultants of the Company. The weighted average exercise price of these options is $0.19. Of this grant, 390,000 options vest as to one-third on the grant date and one-third on each of the first anniversary and the second anniversary of the grant date; 85,000 options vest as to one quarter on the date of grant and one quarter at 90 days, 180 days and 270 days from the grant date. Subsequent to December 31, 2017 and during the year ended March 31, 2018, the Company recorded $348,851 (2017 - $Nil) as additional capital for the issuance of 3,457,740 deferred share units issued to officers in lieu of compensation for past service. Deferred share units represent a commitment to issue restricted shares upon request or termination at some date in the future. Accordingly, the measurement date for this commitment has not been determined and therefore the commitment requires re-measurement at each reporting period until it is fulfilled. Subsequent to December 31, 2017 and during the year ended March 31, 2018, the Company recorded a recovery of $84,000 (2017 -$393,184) as a result of shares forfeited by management. Additionally, subsequent to the end of the period and during the year ended March 31, 2018, the Company recorded $31,186 (2017 - $782,993) as professional fees for services rendered related to common shares issued or to be issued to consultants.

Equipment and Leasehold Impro_2

Equipment and Leasehold Improvements (Tables)	9 Months Ended
	Dec. 31, 2017
Property, Plant and Equipment [Abstract]
Schedule of Equipment and Leasehold Improvements	December 31, 2017 March 31, 2017 Accumulated Accumulated Cost Depreciation Cost Depreciation Computer equipment $ 3,558 $ 2,761 $ 3,558 $ 2,530 Production equipment 67,367 40,419 67,367 35,663 Leasehold improvements 42,290 33,987 42,290 27,194 Total $ 113,215 $ 77,167 $ 113,215 $ 65,387 Net carrying amount $ 36,048 $ 47,828

Convertible Notes (Tables)

Convertible Notes (Tables)	9 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
Schedule of Secured Convertible Notes	The carrying values of the Company’s secured convertible notes consist of the following as of December 31, 2017 and March 31, 2017 respectively: Convertible Notes December 31, 2017 March 31, 2017 USD$50,000 face value convertible note due August 15, 2017 a $ - $ (26,076 ) USD$56,000 face value convertible note due August 18, 2017, b - (16,456 ) USD$50,000 face value convertible notes due June 21, 2018, c (37,009 ) - USD$50,000 face value convertible note due July 25, 2018, d (37,223 ) - USD$20,000 face value convertible note due January 2, 2018, e (24,731 ) - USD$25,000 face value convertible note due January 15,2018, e (29,775 ) - $ (128,738 ) $ (42,532 )

Derivative Liability (Tables)

Derivative Liability (Tables)	9 Months Ended
	Dec. 31, 2017
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Weighted Average Assumptions Used for Fair Value Measurement	The following table sets forth (i) the range of inputs for each significant assumption and (ii) the equivalent, or averages, of each significant assumption as of December 31, 2017: Compound Embedded Derivative: December 31, 2017 March 31, 2017 Stock Price $ 0.071 USD $ 0.23 USD Risk free rate 1.76 % 1.02 % Expected volatility 179 % 308 % Conversion/Exercise price $ 0.07 USD $ 0.145 USD Expected dividend rate 0 % 0 % Expected life (in years) 0.47 0.38 Derivative Liability Warrants December 31, 2017 March 31, 2017 Stock Price $ 0.071 USD N/A Risk free rate 2.20 % N/A Expected volatility 212 % N/A Conversion/Exercise price $ 0.50 USD N/A Expected dividend rate 0 % N/A Expected life (in years) 4.47 N/A

Capital Stock (Tables)

Capital Stock (Tables)	9 Months Ended
	Dec. 31, 2017
Equity [Abstract]
Summary of Warrants Outstanding	As at December 31, 2017, the following warrants were outstanding: Fair Value at December 31, 2017 Expiration Date Number of Warrants Number of Warrants Exercisable Weighted Average Exercise Price of Vested Warrants – Liability December 31, 2018, ii.) 275,000 50,000 USD$ 0.04 $ (0.05 ) $ 2,600 January 17, 2022, iii.) 900,000 900,000 USD$ 0.65 $ (0.83 ) $ 30,600 June 21, 2022, iv.) 200,000 200,000 USD$ 0.50 $ (0.63 ) $ 13,352 July 25, 2022, v.) 200,000 200,000 USD$ 0.50 $ (0.63 ) $ 13,397 1,575,000 1,350,000 $ 0.64 $ 59,949
Schedule of Warrants Activity	The continuity of warrants for the period ended December 31, 2017 as follows: Number Weighted Average of Warrants Exercise Price Balance, March 31, 2017 1,197,500 $ 0.68 Issued 400,000 $ 0.64 Expired, unexercised (22,500 ) $ 1.12 Balance, December 31, 2017 1,575,000 $ 0.64
Schedule of Options Activity	The activities in options outstanding are as noted below: Number of Weighted Average Options Exercise Price Balance, March 31, 2017 695,000 $ 0.99 Granted 850,000 $ 0.15 Balance, December 31, 2017 1,545,000 $ 0.53
Schedule of Stock Options Outstanding and Exercisable	The following table presents information relating to stock options outstanding and exercisable at December 31, 2017. Options Outstanding Options Exercisable Weighted Weighted Average Weighted Average Remaining Average Remaining Number of Contractual Number of Exercise Contractual Exercise Price Options Life (Years) Options Price Life (Years) $ 1.73 185,000 1.96 185,000 $ 1.73 1.96 $ 2.43 85,000 3.02 85,000 $ 2.43 3.02 $ 0.38 425,000 3.82 311,667 $ 0.38 3.82 $ 0.15 850,000 4.83 269,167 $ 0.15 4.83 $ 0.53 1,545,000 4.11 850,833 $ 0.53 3.66

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases	The future commitments pursuant to this lease extension, including property taxes and operating expenses for the fiscal periods ending March 31 are: 2018 (remaining) $ 6,867 2019 $ 28,685 2020 $ 32,763 2021 $ 33,875 2022 $ 23,500
Schedule of Employment Agreements	Salaries will be earned based upon the Company’s success in raising future capital in accordance with the following schedule: Cumulative Funds Raised 1 Effective Monthly Salary % $ 100,000 10.0 % $ 175,000 15.0 % $ 250,000 25.0 % $ 375,000 37.5 % $ 500,000 50.0 % $ 750,000 62.5 % $ 1,000,000 75.0 % $ 1,250,000 87.5 % $ 1,500,000 100.0 %

Financial Instruments (Tables)

Financial Instruments (Tables)	9 Months Ended
	Dec. 31, 2017
Fair Value Disclosures [Abstract]
Summary of Fair Value of Financial Liabilities	The warrants are accounted for as derivative liabilities because the exercise price is denominated in a currency other than the Company’s functional currency. Fair Value at Fair Value Measurement Using December 31, 2017 Level 1 Level 2 Level 3 Derivative liability – Warrants $ 59,949 $ - $ - $ 59,949
Summary of Changes in the Fair Value of Level 3 Financial Liabilities	The table below sets forth a summary of changes in the fair value of the Company’s Level 3 financial liabilities (warrant derivative liability) for the periods ended December 31, 2017 and March 31, 2017: Nine months ended Year ended December 31, 2017 March 31, 2017 Balance at beginning of year $ 236,200 $ 27,479 Derivative instruments granted or vested 41,294 633,000 Derivative instruments exercised - (55,321 ) Change in fair market value, recognized in operations as professional fees (217,545 ) (368,958 ) Balance at end of period $ 59,949 $ 236,200
Schedule of Estimated Fair Value Assumptions	The following are the key weighted average assumptions used in connection with the estimation of fair value as at December 31, 2017: December 31, 2017 March 31, 2017 Number of shares underlying the warrants 1,575,000 1,175,000 Fair market value of the stock $ 0.071 $ 0.3061 Exercise price USD$ 0.5($0.64 ) USD$ 0.5($0.68 ) Expected volatility 212 % 229 % Risk-free interest rate 2.20 % 1.03 % Expected dividend yield 0 % 0 % Expected warrant life (years) 3.64 3.85

Nature of the Business and Go_2

Nature of the Business and Going Concern (Details Narrative) - CAD ($)	Dec. 31, 2017	Mar. 31, 2017
Accounting Policies [Abstract]
Working capital deficiency	$ 595,314	$ 852,514
Accumulated deficit	$ 6,429,592	$ 6,134,941

Equipment and Leasehold Impro_3

Equipment and Leasehold Improvements (Details Narrative) - CAD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Amortization expense	$ 1,662	$ 4,356	$ 11,780	$ 13,068

Equipment and Leasehold Impro_4

Equipment and Leasehold Improvements - Schedule of Equipment and Leasehold Improvements (Details) - CAD ($)	Dec. 31, 2017	Mar. 31, 2017
Property and Equipment, Cost	$ 113,215	$ 113,215
Accumulated Depreciation	77,167	65,387
Property and Equipment, net	36,048	47,828
Computer Equipment [Member]
Property and Equipment, Cost	3,558	3,558
Accumulated Depreciation	2,761	2,530
Production Equipment [Member]
Property and Equipment, Cost	67,367	67,367
Accumulated Depreciation	40,419	35,663
Leasehold Improvements [Member]
Property and Equipment, Cost	42,290	42,290
Accumulated Depreciation	$ 33,987	$ 27,194

Advances from Shareholders (Det

Advances from Shareholders (Details Narrative) - CAD ($)	Dec. 31, 2017	Mar. 31, 2017
Related Party Transactions [Abstract]
Advances from shareholders		$ 22,347

Term Loans (Details Narrative)

Term Loans (Details Narrative) - CAD ($)	Jul. 25, 2017	Jun. 21, 2017	May 04, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016
Term loan bridge financing			$ 40,000
Loan description	One purchase warrant can be exchanged for one common share for USD$0.50 at any time until July 25, 2022.	One purchase warrant can be exchanged for one common share for USD$0.50 at any time until June 21, 2022	bridge financing with a relative of one of the officers of the Company.
Loan maturity, date	Jul. 25, 2018	Jun. 21, 2018	Nov. 30, 2017
Premium interest percent			30.00%
Accretion expenses				$ 75,556	$ 13,941	$ 220,100	$ 22,897
Loan initial maturity date			Aug. 28, 2016
Term Loan [Member]
Accretion expenses				$ 777	$ 2,000	$ 2,930	$ 10,956

Convertible Notes (Details Narr

Convertible Notes (Details Narrative)	Nov. 13, 2017CAD ($)	Nov. 13, 2017USD ($)	Nov. 01, 2017CAD ($)	Nov. 01, 2017USD ($)	Oct. 27, 2017CAD ($)	Oct. 27, 2017USD ($)	Sep. 18, 2017CAD ($)	Sep. 18, 2017USD ($)	Aug. 15, 2017CAD ($)	Aug. 15, 2017USD ($)	Aug. 14, 2017CAD ($)	Aug. 14, 2017USD ($)	Jul. 25, 2017USD ($)$ / sharesshares	Jun. 21, 2017CAD ($)shares	Jun. 21, 2017USD ($)$ / sharesshares	Feb. 14, 2017USD ($)	Nov. 18, 2016CAD ($)	Nov. 18, 2016USD ($)	May 04, 2016	Dec. 31, 2017CAD ($)$ / sharesshares	Dec. 31, 2016CAD ($)	Dec. 31, 2017CAD ($)$ / sharesshares	Dec. 31, 2017USD ($)shares	Dec. 31, 2016CAD ($)	Mar. 31, 2017CAD ($)	Mar. 31, 2015CAD ($)$ / shares	Dec. 31, 2017USD ($)$ / sharesshares	Jul. 25, 2017CAD ($)shares	Jul. 25, 2017USD ($)$ / sharesshares	Mar. 31, 2017USD ($)	Feb. 14, 2017CAD ($)	Feb. 14, 2017USD ($)	Nov. 18, 2016USD ($)
Debt maturity date													Jul. 25, 2018	Jun. 21, 2018	Jun. 21, 2018				Nov. 30, 2017
Proceeds from convertible debt																						$ 578,123		$ 67,595
Debt instrument interest rate																			30.00%
Accretion expenses																				$ 75,556	$ 13,941	220,100		22,897
Convertible note																				128,738		128,738			$ 42,532
Stock issued during period, share | shares													560,000	560,000	560,000
Warrant to purchase of common stock | shares															200,000													200,000	200,000
Value of warrant																						(203,000)		16,042
Warrants [Member]
Value of warrant																										$ 19,290
Warrant exercisable price per share | $ / shares																										$ 1.12
Promissory Note [Member]
Debt total amount paid									$ 67,591
Debt principal amount paid									63,775
Debt interest amount paid									$ 3,816
Accretion expenses																						$ 48,499
Promissory Note [Member] | USD [Member]
Debt total amount paid										$ 53,000
Debt principal amount paid										50,000
Debt interest amount paid										$ 3,000
Promissory Note [Member] | Salamon Partners LLC [Member]
Debt instrument principal amount																															$ 65,350
Debt maturity date																Aug. 15, 2017
Debt instrument interest rate																															12.00%	12.00%
Variable conversion price per share																65.00%
Promissory Note [Member] | Salamon Partners LLC [Member] | USD [Member]
Debt instrument principal amount																																$ 50,000
Proceeds from convertible debt																$ 47,500
Debt transaction cost																$ 2,500
Convertible Note [Member]
Debt maturity date																						Aug. 15, 2017	Aug. 15, 2017		Aug. 15, 2017
Accretion expenses																				13,939		$ 29,086
Convertible note																									$ 26,076
Debt instrument term														1 year	1 year
Stock issued during period, share | shares														200,000	200,000
Debt instrument embedded conversion feature														$ 66,451
Warrant to purchase of common stock | shares															200,000
Warrant term															5 years
Convertible Note [Member] | June 21, 2018 [Member]
Conversion of debt into share | shares														560,000	560,000
Convertible Note [Member] | USD [Member]
Debt instrument principal amount																											$ 50,000			$ 50,000
Debt instrument interest rate															12.00%
Convertible note															$ 500,000
Common stock conversion price per share | $ / shares															$ 0.25
Common stock trading price per share | $ / shares															$ 1
Stock issued during period, value															$ 100,000
Debt instrument embedded conversion feature															50,000
Value of warrant															$ 50,000
Warrant exercisable price per share | $ / shares															$ 0.50
Convertible Note [Member] | USD [Member] | June 21, 2018 [Member]
Common stock conversion price per share | $ / shares															0.10
Convertible notes exercise price per share | $ / shares															$ 0.10
Convertible Note [Member] | GHS Investments, LLC [Member] | Securities Purchase Agreement [Member]
Debt instrument principal amount																	$ 76,382
Debt maturity date																	Aug. 18, 2017	Aug. 18, 2017
Proceeds from convertible debt																	$ 67,595
Debt instrument interest rate																	12.00%																12.00%
Variable conversion price per share																	62.00%	62.00%
Accretion expenses																					11,941	$ 45,854		11,941
Convertible Note [Member] | GHS Investments, LLC [Member] | USD [Member] | Securities Purchase Agreement [Member]
Debt instrument principal amount																																	$ 56,500
Proceeds from convertible debt																		$ 50,000
Convertible Note I [Member]
Debt maturity date																						Aug. 18, 2017	Aug. 18, 2017		Aug. 18, 2017
Debt instrument interest rate																												12.00%	12.00%
Accretion expenses																				11,542		$ 19,798
Convertible note																									$ 16,456			$ 62,535
Debt instrument term													1 year
Stock issued during period, share | shares													200,000
Warrant to purchase of common stock | shares																												200,000	200,000
Warrant term																												5 years	5 years
Convertible Note I [Member] | July 25, 2018 [Member]
Conversion of debt into share | shares													560,000
Convertible Note I [Member] | USD [Member]
Debt instrument principal amount																											$ 56,000			56,000
Convertible note																													$ 50,000
Common stock conversion price per share | $ / shares																													$ 0.25
Common stock trading price per share | $ / shares													$ 1
Stock issued during period, value													$ 100,000
Value of warrant													$ 50,000
Warrant exercisable price per share | $ / shares																													0.50
Convertible Note I [Member] | USD [Member] | July 25, 2018 [Member]
Common stock conversion price per share | $ / shares																													0.10
Convertible notes exercise price per share | $ / shares																													$ 0.10
Convertible Note II [Member]
Debt maturity date	Jan. 15, 2018	Jan. 15, 2018	Jan. 2, 2018	Jan. 2, 2018	Dec. 27, 2017	Dec. 27, 2017	Nov. 20, 2017	Nov. 20, 2017			Oct. 13, 2017	Oct. 13, 2017										Jun. 21, 2018	Jun. 21, 2018		Jun. 21, 2018
Accretion expenses																				50,075		$ 74,533
Convertible note																				$ 37,009		37,009
Debt instrument embedded conversion feature	$ 31,833		$ 25,770		$ 321,850		$ 12,238				$ 67,602											$ 459,293
Conversion of debt into share | shares																						3,639,931	3,639,931
Issuance of common stock, description																						The Company issue 2,541,781 common shares during the fiscal year ending March 31, 2018 with the remaining 1,098,150 issued subsequent to March 31, 2018 (Note 13).	The Company issue 2,541,781 common shares during the fiscal year ending March 31, 2018 with the remaining 1,098,150 issued subsequent to March 31, 2018 (Note 13).
Accretion expense discount to carrying value																						$ 24,458
Amortization of debt discounts																						$ 220,100		$ 22,897
Convertible Note II [Member] | Warrants [Member]
Warrant to purchase of common stock | shares																				159,023		159,023					159,023
Warrant exercisable price per share | $ / shares																				$ 0.75		$ 0.75
Warrants expiration date																				Jan. 2, 2020		Jan. 2, 2020					Jan. 2, 2020
Convertible Note II [Member] | March 31, 2018 [Member]
Stock issued during period, share | shares																						2,541,781	2,541,781
Convertible Note II [Member] | USD [Member]
Debt instrument principal amount																											$ 50,000			$ 50,000
Common stock conversion price per share | $ / shares																											$ 0.10
Debt instrument embedded conversion feature		$ 25,000		$ 20,000		$ 250,000		$ 10,000				$ 53,000											$ 358,000

Convertible Notes - Schedule of

Convertible Notes - Schedule of Secured Convertible Notes (Details) - CAD ($)	Dec. 31, 2017	Jul. 25, 2017	Mar. 31, 2017
Convertible Notes	$ (128,738)		$ (42,532)
Convertible Note [Member]
Convertible Notes			(26,076)
Convertible Note I [Member]
Convertible Notes		$ (62,535)	(16,456)
Convertible Note II [Member]
Convertible Notes	(37,009)
Convertible Note III [Member]
Convertible Notes	(37,223)
Convertible Note IV [Member]
Convertible Notes	(24,731)
Convertible Note V [Member]
Convertible Notes	$ (29,775)

Convertible Notes - Schedule _2

Convertible Notes - Schedule of Secured Convertible Notes (Details) (Parenthetical) - USD ($)	Nov. 13, 2017	Nov. 01, 2017	Oct. 27, 2017	Sep. 18, 2017	Aug. 14, 2017	Jul. 25, 2017	Jun. 21, 2017	May 04, 2016	Dec. 31, 2017	Mar. 31, 2017
Secured convertible note, due date						Jul. 25, 2018	Jun. 21, 2018	Nov. 30, 2017
Convertible Note [Member]
Secured convertible note, due date									Aug. 15, 2017	Aug. 15, 2017
Convertible Note [Member] | USD [Member]
Secured convertible note, face value									$ 50,000	$ 50,000
Convertible Note I [Member]
Secured convertible note, due date									Aug. 18, 2017	Aug. 18, 2017
Convertible Note I [Member] | USD [Member]
Secured convertible note, face value									$ 56,000	$ 56,000
Convertible Note II [Member]
Secured convertible note, due date	Jan. 15, 2018	Jan. 2, 2018	Dec. 27, 2017	Nov. 20, 2017	Oct. 13, 2017				Jun. 21, 2018	Jun. 21, 2018
Convertible Note II [Member] | USD [Member]
Secured convertible note, face value									$ 50,000	$ 50,000
Convertible Note III [Member]
Secured convertible note, due date									Jul. 25, 2018	Jul. 25, 2018
Convertible Note III [Member] | USD [Member]
Secured convertible note, face value									$ 50,000	$ 50,000
Convertible Note IV [Member]
Secured convertible note, due date									Jan. 2, 2018	Jan. 2, 2018
Convertible Note IV [Member] | USD [Member]
Secured convertible note, face value									$ 20,000	$ 20,000
Convertible Note V [Member]
Secured convertible note, due date									Jan. 15, 2018	Jan. 15, 2018
Convertible Note V [Member] | USD [Member]
Secured convertible note, face value									$ 25,000	$ 25,000

Derivative Liability - Schedule

Derivative Liability - Schedule of Weighted Average Assumptions Used for Fair Value Measurement (Details) - $ / shares	9 Months Ended	12 Months Ended
	Dec. 31, 2017	Mar. 31, 2017
Embedded Derivative [Member] | Risk Free Interest Rate [Member]
Fair value assumption percentage	1.76%	1.02%
Embedded Derivative [Member] | Expected volatility [Member]
Fair value assumption percentage	179.00%	308.00%
Embedded Derivative [Member] | Expected Dividend Yield [Member]
Fair value assumption percentage	0.00%	0.00%
Embedded Derivative [Member] | Expected Life (Years) [Member]
Fair value assumption expected term	5 months 20 days	4 months 17 days
Embedded Derivative [Member] | USD [Member]
Stock price	$ 0.071	$ 0.23
Conversion/Exercise price	$ 0.07	$ 0.145
Derivative Liability Warrants [Member] | Risk Free Interest Rate [Member]
Fair value assumption percentage	2.20%	0.00%
Derivative Liability Warrants [Member] | Expected volatility [Member]
Fair value assumption percentage	212.00%	0.00%
Derivative Liability Warrants [Member] | Expected Dividend Yield [Member]
Fair value assumption percentage	0.00%	0.00%
Derivative Liability Warrants [Member] | Expected Life (Years) [Member]
Fair value assumption expected term	4 years 5 months 20 days	0 years
Derivative Liability Warrants [Member] | USD [Member]
Stock price	$ 0.071
Conversion/Exercise price	$ 0.50

Capital Stock (Details Narrativ

Capital Stock (Details Narrative)	Nov. 10, 2017$ / sharesshares	Nov. 08, 2017shares	Jul. 25, 2017CAD ($)shares	Jul. 25, 2017USD ($)$ / sharesshares	Jun. 21, 2017CAD ($)shares	Jun. 21, 2017USD ($)$ / sharesshares	Apr. 09, 2017CAD ($)shares	Apr. 09, 2017USD ($)shares	May 04, 2016	Sep. 10, 2015CAD ($)shares	Sep. 10, 2015USD ($)shares	Dec. 31, 2017CAD ($)shares	Mar. 31, 2017CAD ($)shares
Number convertible note shares issued | $			$ 62,535		$ 66,550							$ 25,245
Number convertible note shares issued, shares			100,000	100,000	100,000	100,000
Commitment fee | $			$ 11,256		$ 13,989
Debt maturity date			Jul. 25, 2018	Jul. 25, 2018	Jun. 21, 2018	Jun. 21, 2018			Nov. 30, 2017
Number of common stock shares issued			560,000	560,000	560,000	560,000
Number of warrants to purchase shares of common stock				200,000		200,000
Debt description			One purchase warrant can be exchanged for one common share for USD$0.50 at any time until July 25, 2022.	One purchase warrant can be exchanged for one common share for USD$0.50 at any time until July 25, 2022.	One purchase warrant can be exchanged for one common share for USD$0.50 at any time until June 21, 2022	One purchase warrant can be exchanged for one common share for USD$0.50 at any time until June 21, 2022			bridge financing with a relative of one of the officers of the Company.
Number of common stock issued for services		1,050,000										26,187
Number of shares cancelled		600,000
Number of common stock issued for services, value | $												$ 4,000
Number of warrants exercisable												1,575,000	1,175,000
Fair value of warrants exercisable | $												$ 71,649	$ 298,700
Fair value of reflected as liability | $												$ 59,949	$ 236,200
Number of common shares issued and outstanding												2,102,056	2,000,628
Number of options outstanding												1,545,000	930,000
Officers and Consultants [Member]
Number of options granted, shares	850,000
Exercise price of options | $ / shares	$ 0.15
Number of options vested, description	Of this grant 680,000 options vest as to one-third on the grant date and one-third on each of the first anniversary and the second anniversary of the grant date; 170,000 options vest as to one quarter on the date of grant and one quarter at 90 days, 180 days and 270 days from the grant date.
Consulting Agreement [Member]
Number of common stock shares issued							3,182,219	3,182,219
Number of common stock issued for services							100,000	100,000
Number of common stock issued for services, value | $							$ 27,186
Equity Purchase Agreement [Member]
Number of shares paid to EPA equal to restricted common shares										50,000	50,000
Restricted common shares, value | $										$ 67,195
USD [Member]
Number convertible note shares issued | $				$ 50,000		$ 50,000
Shares issued price per share | $ / shares				$ 0.50		$ 0.50
USD [Member] | Consulting Agreement [Member]
Number of common stock issued for services, value | $								$ 20,390
USD [Member] | Equity Purchase Agreement [Member]
Committed to purchase up to company's common shares | $											$ 750,000

Capital Stock - Summary of Warr

Capital Stock - Summary of Warrants Outstanding (Details)		Sep. 03, 2014CAD ($)	Dec. 31, 2017CAD ($)$ / sharesshares	Dec. 31, 2017$ / sharesshares
Warrants [Member]
Number of Warrants			1,575,000	1,575,000
Number of Exercisable Warrants			1,350,000	1,350,000
Weighted Average Exercise Price | $ / shares			$ 0.64
Fair Value at December 31, 2017 of Vested Warrants - Liability | $		$ 2,014,050	$ 59,949
December 31, 2018 [Member]
Number of Warrants	[1]		275,000	275,000
Number of Exercisable Warrants	[1]		50,000	50,000
Weighted Average Exercise Price | $ / shares	[1]		$ (0.05)
Fair Value at December 31, 2017 of Vested Warrants - Liability | $	[1]		$ 2,600
December 31, 2018 [Member] | USD [Member]
Weighted Average Exercise Price | $ / shares	[1]			$ 0.04
January 17, 2022 [Member]
Number of Warrants	[2]		900,000	900,000
Number of Exercisable Warrants	[2]		900,000	900,000
Weighted Average Exercise Price | $ / shares	[2]		$ (0.83)
Fair Value at December 31, 2017 of Vested Warrants - Liability | $	[2]		$ 30,600
January 17, 2022 [Member] | USD [Member]
Weighted Average Exercise Price | $ / shares	[2]			$ 0.65
June 21, 2022 [Member]
Number of Warrants	[3]		200,000	200,000
Number of Exercisable Warrants	[3]		200,000	200,000
Weighted Average Exercise Price | $ / shares	[3]		$ (0.63)
Fair Value at December 31, 2017 of Vested Warrants - Liability | $	[3]		$ 13,352
June 21, 2022 [Member] | USD [Member]
Weighted Average Exercise Price | $ / shares	[3]			$ 0.50
July 25,2022 [Member]
Number of Warrants	[4]		200,000	200,000
Number of Exercisable Warrants	[4]		200,000	200,000
Weighted Average Exercise Price | $ / shares	[4]		$ (0.63)
Fair Value at December 31, 2017 of Vested Warrants - Liability | $	[4]		$ 13,397
July 25,2022 [Member] | USD [Member]
Weighted Average Exercise Price | $ / shares	[4]			$ 0.50
[1]	In connection with a consulting agreement with Connectus, Inc. (see Note 10), the Company granted 625,000 common share purchase warrants with each warrant entitling the grantee to acquire one common share in the capital of the Company at an exercise price of USD$0.04 ($0.054) at any time prior to April 1, 2017. Of the warrants granted, 300,000 vested on September 3, 2014 with the unvested portion vesting pro-rata for each USD$250,000 ($335,675) raised in an offering, fully vesting upon USD$1,500,000 ($2,014,050) being raised. The fair value of the 625,000 warrants at the date of grant of $500,000 was estimated using the Black-Scholes option pricing model, based on the following assumptions: expected dividend yield of 0%; expected volatility of 159%; risk free interest rate of 1.25%; and expected term of 3 years. On December 27, 2016, the Company extended the agreement and the expiry date of the warrants to December 31, 2017. On January 23, 2017, the Company approved the vesting of 100,000 warrants of which 50,000 were exercised on March 21, 2017. This leaves a balance of 275,000 warrants remaining under the contract of which 50,000 were exerciseable at March 31, 2018 and March 31, 2017. The Company approved a further extension to the agreement to December 31, 2018, with the vested warrants being extended to March 31, 2019. The fair value of $2,600 of the warrants was estimated at December 31, 2017 using the Black-Scholes model, based on the following assumptions: expected dividend yield of 0%; risk free interest rate of 1.53%; expected volatility of 106.3%; and expected term of 1.0 years.
[2]	During the year ended March 31, 2017, the Company issued 900,000 warrants of the Company valued at $566,100 for services rendered. Each warrant entitled the holder to purchase one common share at an exercise price of USD$$0.65 ($0.82) for a period of 5 years after the date of issuance. The fair value of the warrants at the date of grant of $566,100 was estimated using the Black-Scholes option pricing model, based on the following weighted average assumptions: expected dividend yield of 0%; risk free interest rate of 1.09%; expected volatility of 140%; and expected term of 5 years. The fair value of $30,600 of the warrants was estimated at December 31, 2017 using the Black-Scholes option pricing model, based on the following weighted average assumptions: expected dividend yield of 0%; risk free interest rate of 1.81%; expected volatility of 108.5%; and expected term of 4.05 years.
[3]	On June 21, 2017, the Company issued 200,000 warrants of the Company valued at $23,359 (USD$17,550), pursuant to the financing described in Note 6(c). Each warrant entitles the holder to purchase one common share at an issue price of USD$0.50 for a period of 5 years after the date of issuance. The fair value of the warrants at the date of grant of $23,359 was estimated using the binomial-lattice-based valuation model, based on the following weighted average assumptions: stock price of USD$0.11; expected dividend yield of 0%; risk free interest rate of 1.28%; expected volatility of 223%; and expected term of 5 years. See valuation and assumption as at December 31, 2017 in Note 7.
[4]	On July 25, 2017, the Company issued 200,000 warrants of the Company valued at $17,935 (USD$14,340), pursuant to the financing described in Note 6(d). Each warrant entitles the holder to purchase one common share at an issue price of USD$0.50 for a period of 5 years after the date of issuance. The fair value of the warrants at the date of grant of $17,935 was estimated using the binomial-lattice-based valuation model, based on the following weighted average assumptions: stock price of USD$0.11; expected dividend yield of 0%; risk free interest rate of 1.90%; expected volatility of 226%; and expected term of 5 years. See valuation and assumption as at December 31, 2017 in Note 7.

Capital Stock - Summary of Wa_2

Capital Stock - Summary of Warrants Outstanding (Details) (Parenthetical)	Jul. 25, 2017	Jun. 25, 2017CAD ($)shares	Jun. 25, 2017USD ($)$ / sharesshares	Jun. 21, 2017CAD ($)shares	Jun. 21, 2017USD ($)$ / sharesshares	Mar. 21, 2017shares	Jan. 23, 2017shares	May 04, 2016	Sep. 03, 2014CAD ($)shares	Sep. 03, 2014USD ($)shares	Dec. 31, 2017CAD ($)$ / sharesshares	Dec. 31, 2016CAD ($)	Mar. 31, 2017CAD ($)$ / sharesshares	Mar. 31, 2015CAD ($)$ / sharesshares	Dec. 31, 2017$ / shares	Mar. 31, 2017$ / shares
Fair value of warrants at grant											$ (203,000)	$ 16,042
Debt description	One purchase warrant can be exchanged for one common share for USD$0.50 at any time until July 25, 2022.			One purchase warrant can be exchanged for one common share for USD$0.50 at any time until June 21, 2022	One purchase warrant can be exchanged for one common share for USD$0.50 at any time until June 21, 2022			bridge financing with a relative of one of the officers of the Company.
Warrants [Member]
Number of common shares purchase warrants exercised during period | shares														27,500
Fair value of warrants at grant														$ 19,290
Warrant exercised per share | $ / shares														$ 1.12
Expected term														2 years 10 months 6 days
Dividend yield														0.00%
Risk-free interest rate														1.14%
Expected volatility														182.00%
Warrant expiration date														Jun. 6, 2017
Number of warrant vested, shares | shares							100,000		300,000	300,000
Unvested portion vesting pro-rata raised in offering value									$ 335,675
Fully vesting upon raised offering value									$ 2,014,050
Number of warrants exercised | shares						50,000
Warrants [Member] | March 31, 2018 [Member]
Remaining after exercise of warrants | shares											275,000
Number of warrant exercisable | shares											50,000
Warrants [Member] | USD [Member]
Unvested portion vesting pro-rata raised in offering value										$ 250,000
Fully vesting upon raised offering value										$ 1,500,000
Warrants [Member] | Connectus, Inc. [Member]
Fair value of warrants at grant											$ 2,600
Expected term											1 year
Dividend yield											0.00%
Risk-free interest rate											1.53%
Expected volatility											106.30%
Number of warrant vested, shares | shares							100,000
Warrants [Member] | Connectus, Inc. [Member] | Consulting Agreement [Member]
Number of common shares purchase warrants exercised during period | shares											625,000
Fair value of warrants at grant											$ 500,000
Warrant exercised per share | $ / shares											$ 0.054
Expected term											3 years
Dividend yield											0.00%
Risk-free interest rate											1.25%
Expected volatility											159.00%
Warrants [Member] | Connectus, Inc. [Member] | Consulting Agreement [Member] | USD [Member]
Warrant exercised per share | $ / shares															$ 0.04
Warrants [Member] | Minimum [Member]
Expected term														2 years 1 month 24 days
Warrants [Member] | Maximum [Member]
Expected term														3 years
Warrants [Member] | Officer [Member]
Number of common shares purchase warrants exercised during period | shares														22,500
Warrants [Member]
Fair value of warrants at grant		$ 17,935		$ 23,359							$ 30,600		$ 566,100
Warrant exercised per share | $ / shares													$ 0.82
Expected term		5 years	5 years	5 years	5 years						4 years 18 days		5 years
Dividend yield		0.00%	0.00%	0.00%	0.00%						0.00%		0.00%
Risk-free interest rate		1.90%	1.90%	1.28%	1.28%						1.81%		1.09%
Expected volatility		226.00%	226.00%	223.00%	223.00%						108.50%		140.00%
Number of warrant exercisable | shares													50,000
Number shares issued fro warrants, shares | shares		200,000	200,000	200,000	200,000								900,000
Debt description													Each warrant entitled the holder to purchase one common share at an exercise price of USD$$0.65 ($0.82) for a period of 5 years after the date of issuance.
Number shares issued for warrants		$ 17,935		$ 23,359
Warrants [Member] | USD [Member]
Warrant exercised per share | $ / shares			$ 0.50		$ 0.50											$ 0.65
Weighted average stock price, warrants | $ / shares			$ 0.11		$ 0.11
Number shares issued for warrants			$ 14,340		$ 17,550

Capital Stock - Schedule of War

Capital Stock - Schedule of Warrants Activity (Details) - Warrants [Member]	9 Months Ended
	Dec. 31, 2017$ / sharesshares
Number of Warrants, Beginning Balance | shares	1,197,500
Number of Warrants, Issued | shares	400,000
Number of Warrants, Expired, unexercised | shares	(22,500)
Number of Warrants, Ending Balance | shares	1,575,000
Weighted Average Exercise Price, Beginning Balance | $ / shares	$ 0.68
Weighted Average Exercise Price, Issued | $ / shares	0.64
Weighted Average Exercise Price, Expired, unexercised | $ / shares	1.12
Weighted Average Exercise Price, Ending Balance | $ / shares	$ 0.64

Capital Stock - Schedule of Opt

Capital Stock - Schedule of Options Activity (Details)	9 Months Ended
	Dec. 31, 2017$ / sharesshares
Shares Outstanding, Beginning	930,000
Shares Outstanding, Ending	1,545,000
Options [Member]
Shares Outstanding, Beginning	695,000
Shares Outstanding, Granted	850,000
Shares Outstanding, Ending	1,545,000
Weighted Average Exercise Price, Beginning | $ / shares	$ 0.99
Weighted Average Exercise Price, Granted | $ / shares	0.15
Weighted Average Exercise Price, Ending | $ / shares	$ 0.53

Capital Stock - Schedule of Sto

Capital Stock - Schedule of Stock Options Outstanding and Exercisable (Details)	9 Months Ended
	Dec. 31, 2017$ / sharesshares
Exercise Price, Options Outstanding | $ / shares	$ 0.53
Number of Options Outstanding | shares	1,545,000
Weighted Average Remaining Contractual Life (Years), Options Outstanding	4 years 1 month 9 days
Number of Options Exercisable | shares	850,833
Weighted Average Exercise Price, Options Exercisable | $ / shares	$ 0.53
Weighted Average Remaining Contractual Life (Years), Options Exercisable	3 years 7 months 28 days
Exercise Price One [Member]
Exercise Price, Options Outstanding | $ / shares	$ 1.73
Number of Options Outstanding | shares	185,000
Weighted Average Remaining Contractual Life (Years), Options Outstanding	1 year 11 months 15 days
Number of Options Exercisable | shares	185,000
Weighted Average Exercise Price, Options Exercisable | $ / shares	$ 1.73
Weighted Average Remaining Contractual Life (Years), Options Exercisable	1 year 11 months 15 days
Exercise Price Two [Member]
Exercise Price, Options Outstanding | $ / shares	$ 2.43
Number of Options Outstanding | shares	85,000
Weighted Average Remaining Contractual Life (Years), Options Outstanding	3 years 7 days
Number of Options Exercisable | shares	85,000
Weighted Average Exercise Price, Options Exercisable | $ / shares	$ 2.43
Weighted Average Remaining Contractual Life (Years), Options Exercisable	3 years 7 days
Exercise Price Three [Member]
Exercise Price, Options Outstanding | $ / shares	$ 0.38
Number of Options Outstanding | shares	425,000
Weighted Average Remaining Contractual Life (Years), Options Outstanding	3 years 9 months 25 days
Number of Options Exercisable | shares	311,667
Weighted Average Exercise Price, Options Exercisable | $ / shares	$ 0.38
Weighted Average Remaining Contractual Life (Years), Options Exercisable	3 years 9 months 25 days
Exercise Price Four [Member]
Exercise Price, Options Outstanding | $ / shares	$ 0.15
Number of Options Outstanding | shares	850,000
Weighted Average Remaining Contractual Life (Years), Options Outstanding	4 years 9 months 29 days
Number of Options Exercisable | shares	269,167
Weighted Average Exercise Price, Options Exercisable | $ / shares	$ 0.15
Weighted Average Remaining Contractual Life (Years), Options Exercisable	4 years 9 months 29 days

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - CAD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Taxable income under canadian Federal
Net operating loss carry forwards	$ 3,948,000		$ 3,948,000
Operating loss carryforward expiration			expire between 2019 and 2037

Commitments and Contingencies_2

Commitments and Contingencies (Details Narrative)

Nov. 30, 2018CAD ($)

Aug. 15, 2017CAD ($)

Aug. 08, 2017CAD ($)

May 08, 2017USD ($)shares

Apr. 09, 2017USD ($)shares

Mar. 27, 2017CAD ($)

Mar. 27, 2017USD ($)

Mar. 13, 2017CAD ($)

Feb. 23, 2017CAD ($)

Jan. 23, 2017shares

Jan. 10, 2017$ / sharesshares

May 19, 2016CAD ($)shares

Sep. 03, 2014CAD ($)shares

Sep. 03, 2014USD ($)shares

Apr. 23, 2014CAD ($)

Dec. 02, 2013

Dec. 31, 2017CAD ($)$ / shares

Dec. 31, 2016CAD ($)

Dec. 31, 2017CAD ($)$ / sharesshares

Dec. 31, 2016CAD ($)

Mar. 31, 2016shares

Dec. 31, 2017$ / shares

Apr. 19, 2017

Jan. 10, 2017$ / shares

May 19, 2016USD ($)

Operating lease term

5 years

Operating lease expiry date

Nov. 30, 2018

Payment for rent

$ 1,390

Property taxes operating expenses

$ 847

Operating lease expiration, description

The Company has agreed to extend the lease to November 30, 2021.

Rental expenses

$ 6,544

$ 6,500

$ 19,679

$ 19,499

Payment for commitments

30,000

Gross sales

1,000,000

Consulting fee

418,875

427,000

Ownership percentage

96.00%

Commitment fee

30,000

30,000

Work fee

29,529

$ 258,484

69,623

$ 743,738

2017 - 2018 [Member]

Commitment fee

24,000

24,000

2018 - 2019 [Member]

Commitment fee

66,000

66,000

2019 - 2020 [Member]

Commitment fee

$ 60,000

$ 60,000

Cannabis Oil Extraction Equipment [Member]

Estimated cost of purchase and installation

$ 1,450,000

Connectus, Inc. [Member]

Number of common stock shares issued for compensation | shares

93,000

The Eversull Group Inc [Member]

Number of restricted common shares | shares

100,000

Percentage of introduction fee

3.00%

Avanti Rx Analytics Inc [Member]

Ownership percentage

4.00%

Carter, Terry & Company [Member]

Agreement term

2 years

Number of restricted common shares | shares

150,000

Percentage of placement fee equal to gross purchase price paid for equity

10.00%

Percentage of gross funds

8.00%

Percentage of captial raised

4.00%

Kernaghan and Partners Ltd. [Member]

Warrants term

2 years

Work fee

$ 25,000

Agency fee, description

cash commission (the “Agency Fee”) of 6% of the gross proceeds from the sale of common shares pursuant to the offering, except for sales to persons on the “President’s List”, in respect of which the commission shall be reduced to 2% of the gross proceeds received from such persons

Percentage of placement fee is equal to gross proceeds

6.00%

Kernaghan and Partners Ltd. [Member] | Minimum [Member]

Percentage of placement fee is equal to gross proceeds

2.00%

USD [Member] | The Eversull Group Inc [Member]

Minimum monthly retainer

$ 2,000

USD [Member] | Carter, Terry & Company [Member]

Gross sales

$ 1,000,000

USD [Member] | Carter, Terry & Company [Member] | Maximum [Member]

Gross sales

$ 1,000,000

Warrants [Member]

Number of warrants exercisable per share | $ / shares

$ 0.054

$ 0.054

Number of warrants granted vested, shares | shares

100,000

300,000

300,000

Unvested portion vesting pro-rata raised in offering value

$ 335,675

Vested offering costs

$ 2,014,050

$ 59,949

Number of warrants vested during the period | shares

100,000

300,000

300,000

Warrants [Member] | January 15, 2018 [Member]

Warrant expiry date

Dec. 31, 2018

Warrant expiration description

The Company agreed to extend the vested warrants to March 31, 2019.

Warrants [Member] | Connectus, Inc. [Member]

Number of warrants granted vested, shares | shares

100,000

Number of warrants vested during the period | shares

100,000

Warrants [Member] | USD [Member]

Number of warrants exercisable per share | $ / shares

$ 0.04

Unvested portion vesting pro-rata raised in offering value

$ 250,000

Vested offering costs

$ 1,500,000

Consulting Agreements [Member] | Warrants [Member]

Number of warrants issued during the period | shares

625,000

Warrants term

3 years

Employment Agreements [Member]

Payment for commitments

$ 427,000

Contingent payments

$ 600,000

Consulting Agreement [Member]

Number of warrants issued during the period | shares

900,000

Number of warrants exercisable per share | $ / shares

$ 0.86

Warrants term

5 years

Consulting Agreement [Member] | Agent [Member]

Available for sale combination of equity and or debt

$ 13,427,000

Agreement term

1 year

Number of restricted common shares | shares

100,000

Percentage of placement fee equal to gross purchase price paid for equity

8.00%

8.00%

Percentage of administrative fee of gross purchase price paid for equity

4.00%

4.00%

Percentage of placement fee

4.00%

4.00%

Percentage of common stock shares issuable upon exercise of conversion of all securities

8.00%

8.00%

Consulting Agreement [Member] | USD [Member]

Number of warrants exercisable per share | $ / shares

$ 0.65

Consulting Agreement [Member] | USD [Member] | Agent [Member]

Available for sale combination of equity and or debt

$ 10,000,000

Three Year Sponsored Research Contract [Member]

Payment for commitments

$ 130,000

$ 30,000

Payment for contribution

$ 130,000

Payments to researcher

10,000

Gross sales

50,000

Three Year Sponsored Research Contract [Member] | Maximum [Member]

Gross sales

1,000,000

Three Year Sponsored Research Contract [Member] | Year One [Member]

Payment for contribution

130,000

Three Year Sponsored Research Contract [Member] | Year Two [Member]

Payment for contribution

130,000

Three Year Sponsored Research Contract [Member] | Year Three [Member]

Payment for contribution

70,000

Three Year Sponsored Research Contract [Member] | U.S. Patent Office [Member]

Amount for patent

40,000

Three Year Sponsored Research Contract [Member] | After First Commercial Sale [Member]

Amount for patent

$ 50,000

Four Year Sponsored Research Contract [Member]

Payment for commitments

$ 230,000

80,000

Payment for contribution

$ 210,000

Payments to researcher

10,000

Gross sales

50,000

Four Year Sponsored Research Contract [Member] | Maximum [Member]

Gross sales

1,000,000

Four Year Sponsored Research Contract [Member] | Year One [Member]

Payment for contribution

210,000

Four Year Sponsored Research Contract [Member] | Year Two [Member]

Payment for contribution

210,000

Four Year Sponsored Research Contract [Member] | Year Three [Member]

Payment for contribution

210,000

Four Year Sponsored Research Contract [Member] | U.S. Patent Office [Member]

Amount for patent

40,000

Four Year Sponsored Research Contract [Member] | Year Three [Member]

Payment for contribution

62,500

Four Year Sponsored Research Contract [Member] | After First Commercial Sale [Member]

Amount for patent

$ 50,000

One Year Agreement [Member]

Claim amount

$ 29,941

One Year Agreement [Member] | USD [Member]

Consulting fee

$ 5,500

Mitacs Accelerate Program [Member]

Project cost

400,000

Cash contribution

180,000

Project cost awarded amount

220,000

Payable of project cost awarded

$ 400,000

Project term

2 years

2019 [Member]

Rental expenses

$ 1,853

2020 [Member]

Rental expenses

1,946

2021 [Member]

Rental expenses

$ 2,039

Commitments and Contingencies -

Commitments and Contingencies - Schedule of Future Minimum Rental Payments for Operating Leases (Details)	Dec. 31, 2017CAD ($)
Commitments and Contingencies Disclosure [Abstract]
2018 (remaining)	$ 6,867
2,019	28,685
2,020	32,763
2,021	33,875
2,022	$ 23,500

Commitments and Contingencies_3

Commitments and Contingencies - Schedule of Employment Agreements (Details)	9 Months Ended
	Dec. 31, 2017CAD ($)
Scenario One [Member]
Commitments	Cumulative funds raised is inclusive of all sources including without limitation capital raised, grants received, revenue recorded, debt raised, and assets sold. The 62.5% threshold was reached during the the period ended December 31, 2017; however, the Company has further deferred any regular commitments for salaries until the Company has sufficient liquidity to sustain salary payments on an ongoing basis. The Board will on a periodic basis as funds are available make non regular payments. For the period ended December 31, 2017, no salary commitments were accrued or expensed in the condensed interim statements of operations (December 31, 2016 - $Nil).
Cumulative fund raised	$ 100,000
Percentage of effective monthly salary	10.00%
Scenario Two [Member]
Commitments	Cumulative funds raised is inclusive of all sources including without limitation capital raised, grants received, revenue recorded, debt raised, and assets sold. The 62.5% threshold was reached during the the period ended December 31, 2017; however, the Company has further deferred any regular commitments for salaries until the Company has sufficient liquidity to sustain salary payments on an ongoing basis. The Board will on a periodic basis as funds are available make non regular payments. For the period ended December 31, 2017, no salary commitments were accrued or expensed in the condensed interim statements of operations (December 31, 2016 - $Nil).
Cumulative fund raised	$ 175,000
Percentage of effective monthly salary	15.00%
Scenario Three [Member]
Commitments	Cumulative funds raised is inclusive of all sources including without limitation capital raised, grants received, revenue recorded, debt raised, and assets sold. The 62.5% threshold was reached during the the period ended December 31, 2017; however, the Company has further deferred any regular commitments for salaries until the Company has sufficient liquidity to sustain salary payments on an ongoing basis. The Board will on a periodic basis as funds are available make non regular payments. For the period ended December 31, 2017, no salary commitments were accrued or expensed in the condensed interim statements of operations (December 31, 2016 - $Nil).
Cumulative fund raised	$ 250,000
Percentage of effective monthly salary	25.00%
Scenario Four [Member]
Commitments	Cumulative funds raised is inclusive of all sources including without limitation capital raised, grants received, revenue recorded, debt raised, and assets sold. The 62.5% threshold was reached during the the period ended December 31, 2017; however, the Company has further deferred any regular commitments for salaries until the Company has sufficient liquidity to sustain salary payments on an ongoing basis. The Board will on a periodic basis as funds are available make non regular payments. For the period ended December 31, 2017, no salary commitments were accrued or expensed in the condensed interim statements of operations (December 31, 2016 - $Nil).
Cumulative fund raised	$ 375,000
Percentage of effective monthly salary	37.50%
Scenario Five [Member]
Commitments	Cumulative funds raised is inclusive of all sources including without limitation capital raised, grants received, revenue recorded, debt raised, and assets sold. The 62.5% threshold was reached during the the period ended December 31, 2017; however, the Company has further deferred any regular commitments for salaries until the Company has sufficient liquidity to sustain salary payments on an ongoing basis. The Board will on a periodic basis as funds are available make non regular payments. For the period ended December 31, 2017, no salary commitments were accrued or expensed in the condensed interim statements of operations (December 31, 2016 - $Nil).
Cumulative fund raised	$ 500,000
Percentage of effective monthly salary	50.00%
Scenario Six [Member]
Commitments	Cumulative funds raised is inclusive of all sources including without limitation capital raised, grants received, revenue recorded, debt raised, and assets sold. The 62.5% threshold was reached during the the period ended December 31, 2017; however, the Company has further deferred any regular commitments for salaries until the Company has sufficient liquidity to sustain salary payments on an ongoing basis. The Board will on a periodic basis as funds are available make non regular payments. For the period ended December 31, 2017, no salary commitments were accrued or expensed in the condensed interim statements of operations (December 31, 2016 - $Nil).
Cumulative fund raised	$ 750,000
Percentage of effective monthly salary	62.50%
Scenario Seven [Member]
Commitments	Cumulative funds raised is inclusive of all sources including without limitation capital raised, grants received, revenue recorded, debt raised, and assets sold. The 62.5% threshold was reached during the the period ended December 31, 2017; however, the Company has further deferred any regular commitments for salaries until the Company has sufficient liquidity to sustain salary payments on an ongoing basis. The Board will on a periodic basis as funds are available make non regular payments. For the period ended December 31, 2017, no salary commitments were accrued or expensed in the condensed interim statements of operations (December 31, 2016 - $Nil).
Cumulative fund raised	$ 1,000,000
Percentage of effective monthly salary	75.00%
Scenario Eight [Member]
Commitments	Cumulative funds raised is inclusive of all sources including without limitation capital raised, grants received, revenue recorded, debt raised, and assets sold. The 62.5% threshold was reached during the the period ended December 31, 2017; however, the Company has further deferred any regular commitments for salaries until the Company has sufficient liquidity to sustain salary payments on an ongoing basis. The Board will on a periodic basis as funds are available make non regular payments. For the period ended December 31, 2017, no salary commitments were accrued or expensed in the condensed interim statements of operations (December 31, 2016 - $Nil).
Cumulative fund raised	$ 1,250,000
Percentage of effective monthly salary	87.50%
Scenario Nine [Member]
Commitments	Cumulative funds raised is inclusive of all sources including without limitation capital raised, grants received, revenue recorded, debt raised, and assets sold. The 62.5% threshold was reached during the the period ended December 31, 2017; however, the Company has further deferred any regular commitments for salaries until the Company has sufficient liquidity to sustain salary payments on an ongoing basis. The Board will on a periodic basis as funds are available make non regular payments. For the period ended December 31, 2017, no salary commitments were accrued or expensed in the condensed interim statements of operations (December 31, 2016 - $Nil).
Cumulative fund raised	$ 1,500,000
Percentage of effective monthly salary	100.00%

Commitments and Contingencies_4

Commitments and Contingencies - Schedule of Employment Agreements (Details) (Parenthetical) - CAD ($)	9 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Threshold percentage	62.50%
Accrued expenses

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - CAD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Mar. 31, 2017
Advance from related party	$ 54,596		$ 54,596
Amount receivable from an officer		$ 9,356		$ 9,356
Bad debt recovery			8,300
Three Officers [Member]
Advance from related party	$ 54,596	$ 21,064	$ 54,596	$ 21,064

Financial Instruments (Details

Financial Instruments (Details Narrative)	9 Months Ended
	Dec. 31, 2017CAD ($)$ / sharesshares	Dec. 31, 2017$ / shares	Mar. 31, 2017CAD ($)	Dec. 31, 2016CAD ($)	Mar. 31, 2016CAD ($)
Cash	$ 5,139		$ 87	$ 2,850	$ 173
Current liabilities	688,736		897,442
Warrant liability	59,949		236,200
Term loan	51,223		48,894
Convertible note	74,232		26,076
Short term convertible notes	54,506
Derivative liability	$ 65,863		260,677
Consulting and Investment Agreements [Member]
Warrants exercise price | $ / shares	$ 0.63
Consulting and Investment Agreements [Member] | Connectus Warrants [Member]
Warrants exercise price | $ / shares	0.05
Consulting and Investment Agreements [Member] | Midtown Warrants [Member]
Warrants exercise price | $ / shares	$ 0.83
Consulting and Investment Agreements [Member] | USD [Member]
Warrants exercise price | $ / shares		$ 0.50
Consulting and Investment Agreements [Member] | USD [Member] | Connectus Warrants [Member]
Warrants exercise price | $ / shares		0.04
Consulting and Investment Agreements [Member] | USD [Member] | Midtown Warrants [Member]
Warrants exercise price | $ / shares		$ 0.65
Canadian Chartered Bank [Member]
Cash	$ 5,139		$ 87
Maximum [Member]
Contractual maturities	30 days
Maximum [Member] | Consulting and Investment Agreements [Member]
Warrants to purchase, shares | shares	1,575,000
Maximum [Member] | Canadian Deposit Insurance Corporation [Member]
Cash deposits	$ 100,000

Financial Instruments - Summary

Financial Instruments - Summary of Fair Value of Financial Liabilities (Details) - Warrant Liability [Member]	Dec. 31, 2017CAD ($)
Derivative liability – Warrants	$ 59,949
Level 1 [Member]
Derivative liability – Warrants
Level 2 [Member]
Derivative liability – Warrants
Level 3 [Member]
Derivative liability – Warrants	$ 59,949

Financial Instruments - Summa_2

Financial Instruments - Summary of Changes in the Fair Value of Level 3 Financial Liabilities (Details) - Warrant Liability [Member] - CAD ($)	9 Months Ended	12 Months Ended
	Dec. 31, 2017	Mar. 31, 2017
Balance at beginning of year	$ 236,200	$ 27,479
Derivative instruments granted or vested	41,294	633,000
Derivative instruments exercised		(55,321)
Change in fair market value, recognized in operations as professional fees	(217,545)	(368,958)
Balance at end of year	$ 59,949	$ 236,200

Financial Instruments - Schedul

Financial Instruments - Schedule of Estimated Fair Value Assumptions (Details) - Warrant Liability [Member]	9 Months Ended	12 Months Ended
	Dec. 31, 2017$ / sharesshares	Mar. 31, 2017$ / sharesshares	Dec. 31, 2017$ / shares	Mar. 31, 2017$ / shares
Number of shares underlying the warrants | shares	1,575,000	1,175,000
Fair market value of the stock	$ 0.071	$ 0.3061
Measurement Input, Exercise Price [Member]
Fair value assumptions, measurement input, per share	$ 0.64	$ 0.68
Measurement Input, Exercise Price [Member] | USD [Member]
Fair value assumptions, measurement input, per share			$ 0.5	$ 0.5
Expected volatility [Member]
Fair value assumptions, measurement input, percentages	212.00%	229.00%	212.00%	229.00%
Risk Free Interest Rate [Member]
Fair value assumptions, measurement input, percentages	2.20%	1.03%	2.20%	1.03%
Expected Dividend Yield [Member]
Fair value assumptions, measurement input, percentages	0.00%	0.00%	0.00%	0.00%
Expected Life (Years) [Member]
Fair value assumptions, measurement input, term	3 years 7 months 21 days	3 years 10 months 6 days

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - CAD ($)

Oct. 01, 2018

Jul. 06, 2018

Apr. 01, 2018

Jan. 15, 2018

Nov. 10, 2017

Jul. 25, 2017

Jun. 21, 2017

Jan. 23, 2017

Sep. 03, 2014

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2017

Dec. 31, 2016

Mar. 31, 2018

Mar. 31, 2017

Mar. 31, 2015

Convertible note

$ 128,738

$ 128,738

$ 42,532

Consulting fee

$ 29,529

$ 258,484

69,623

$ 743,738

Number of warrants to purchase shares of common stock

200,000

200,000

Number of common stock shares issued

560,000

560,000

Additional paid in capital for options

$ 81,448

Officers and Consultants [Member]

Number of options granted, shares

850,000

Exercise price of options

$ 0.15

Warrants [Member]

Warrants exercise price

$ 1.12

Number of warrant vested, shares

100,000

300,000

Stock Based Compensation [Member] | Director Officers [Member]

Additional paid in capital for options

Number of stock options forfeited by management

393,184

Stock Based Compensation [Member] | Consultants [Member]

Consulting fee

$ 782,993

Subsequent Event [Member]

Number of warrants to purchase shares of common stock

115,438

Warrants exercise price

$ 0.75

Commitment to issue common shares

230,876

Warrants expiration date

Jan. 2, 2020

Subsequent Event [Member] | Officers and Consultants [Member]

Number of options granted, shares

475,000

Exercise price of options

$ 0.19

Number of warrant vested, shares

390,000

Subsequent Event [Member] | Officers and Consultants [Member] | With in 90 Days [Member]

Number of warrant vested, shares

85,000

Subsequent Event [Member] | Officer [Member]

Number of Deferred Share Units

3,457,740

Subsequent Event [Member] | Arm's Length Individual [Member] | Stock Incentive Plan [Member]

Number of warrants to purchase shares of common stock

50,000

Warrants exercise price

$ 0.75

Number of restricted stock issued

50,000

Warrants expiration date

Oct. 26, 2020

Subsequent Event [Member] | Edgewater Consulting Corp [Member]

Consulting fee

$ 52,355

Number of warrants to purchase shares of common stock

41,885

Warrants exercise price

$ 0.75

Number of options granted, shares

150,000

Exercise price of options

$ 0.50

Provision of consulting services

$ 3,000

Subsequent Event [Member] | Stock Based Compensation [Member] | Director Officers [Member]

Additional paid in capital for options

$ 348,851

Number of stock options forfeited by management

84,000

Subsequent Event [Member] | Stock Based Compensation [Member] | Consultants [Member]

Consulting fee

$ 31,186

Subsequent Event [Member] | Convertible Debt [Member]

Convertible note

$ 100,000

Shares issued price per share

$ 0.25

Subsequent Event [Member] | Convertible Debt [Member] | Private Placement [Member]

Shares issued price per share

$ 0.40

Amount of proceeds raised from placement

$ 947,117

Description on exchange of shares

In addition, the Company completed a private placement in the amount of $947,117 issued at $0.40 per common share plus one-half warrant. A whole warrant can be exchanged for one common share at $0.75 share up until October 26, 2020.

Subsequent Event [Member] | Convertible Debt [Member] | Private Placement [Member] | Warrants [Member]

Shares issued price per share

$ 0.75